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ABSTRACT
The ability of Ehrlich ascites tumor cells to take up glucose
increased progressively during the course of tumor development in
vivo. Simultaneously as the rate of glucose uptake rose, the density
of glucose-reversible binding sites for cytochalasin B on cell
membrane was also found increased.
In its stereospecificity requirement towards competing sugars
and in its sensitivity to phloretin and diethylstilbestrol, this
class of glucose-sensitive cytochalasin B binding sites resembled the
putative glucose carriers identified in various other cell systems
and may represent the glucose transporters of Ehrlich ascites tumor
cells.
Glucose carriers on tumor cells showed less content in strepto-
zotocin-induced diabetic mice and higher content in insulin-induced
hypoglycaemic mice. For in vitro studies, insulin had no effect on
the content of glucose carriers while glucagon and glucocorticoid
could reduce the carrier content in Ehrlich ascites tumor cells.
In another in vitro studies, low glucose concentration in the medium
could increase the glucose carrier number, and by contrast, high
glucose concentration in medium could decrease the number of glucose
carriers in Ehrlich ascites tumor cells.
Methotrexate arrested the tumor growth, inhibited glucose uptake
and reduced the number of glucose carriers in Ehrlich ascites tumor
cells in vivo. In both methotrexate-treated and untreated cells, the
magnitude of changes in number of glucose carriers closely paralleled
and sufficiently accounted for the magnitude of changes in glucose
uptake. Qualitative changes in the turnover and affinity for sub-
strate of the carrier molecules and of transport process need not
be invoked.
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1INTRODUCTION
I. Glucose metabolism in tumor cells
Tumor cells usually have a characteristically different
glucose metabolism from those of normal cells, in that they
metabolize glucose mainly via glycolysis even in the presence
of oxygen (Warburg 1956). This phenomenon is termed aerobic
glycolysis. Whether high aerobic glycolysis is essential for
tumor growth or related to the malignant transformation has not
yet been clearly established.
However Eltzina (Eltzina 1960) showed that respiration
alone was able to maintain in cancer cells an optimal rate
of ATP resynthesis and to ensure energetically amino acid incor-
(Eltzina 1953). Shapot (Shapot 1972) suggested that in the
tumor bearing organism, the actual condition for optimal
respiration can be far from favorable. For example, the P02 in
various human tumor of skin of more than 200 patients was found
to be 25% or less of that of the simultaneously examined normal
adjecent skin (Urbach 1956). Oxygen even was apparently absent
in the ascites fluid of Ehrlich ascites tumor in vivo (Warburg
and Hiepler 1952) and almost anaerobic condition was maintained
in the ascites fluid in vivo (Shapot 1965). When oxygen was
introduced intraperitoneally into the mice bearing Ehrlich
ascites tumor, the concentration of lactic acid in the ascites
fluid dropped gradually and glucose appeared (Shapot 1972).
This implied, in vivo, respiration of cancer cells under usual
conditions is so weak because oxygen supply was insufficient.
poration into their protein to the same extent as glycolysis
2Only an extra oxygen supply enabled the cancer cells to undergo
respiration and thereby partially blocked glycolysis thus reduced
the glucose consumption. However, many evidences (Warburg 1956
Racker 1976) showed that tumor cells metabolized glucose to
lactic acid even in the presence of oxygen. The precise
mechanism of aerobic glycolysis in the tumor cells remains
unknown.
Another characteristically different glucose metabolism
in tumor cell is that tumor cells have higher glucose uptake
rate than normal cell types (Stein 1967 Fain 1964 Corfford
and Renold 1965 Crane et aZ 1957 Saha and Coe 1967 Kolber
and LeFevre 1967). For example, Ehrlich ascites tumor cells
from in vitro culture (Kaminskas 1979) or washed from the
peritoneal cavities of mice had higher glucose uptake rate
than normal cells (Crane,Field and Cori 1957 Saha and Coe 1967
Rubin 1971). Chick embryo fibroblasts infected with Rous
sarcoma virus was also found to be characterized by a higher
uptake rate of 2-deoxy--D-glucose accompanied with the trans-
formation than normal uninfected cells growing at the same rate
(Martin et al 1971).
It was found that glucose uptake in various tumor and
normal cell lines including Ehrlich ascites tumor cells is
mediated through two.distinglished mechanism, namely unsaturable
diffusion and saturably facilitated diffusion (Saha and Coe
1967 Kolber and LeFevre 1967 Lieb and Stein 1970 Renner,
Plagemann and Bernlohr 1972 Plagemann and Richey 1974
Hantanaka 1974). In general, unsaturable diffusion is caused
3by simple diffusion of glucose from extracellular environment
into intracellular environment due to the gradient between
these two environments. The saturably facilitated diffusion
is a carrier-mediated uptake process and follows Michaelis-
Menten kinetics.
II. The use of Ehrlich ascites tumor cells as the experimental
tumor model
In the following experiments, the tumor model employed is
Ehrlich ascites tumor in mice. The origin of Ehrlich ascites
tumor is a solid line of Ehrlich carcinoma, an epithetial
mammary carcinoma of mice. It was first converted into ascites
form by Lowenthal in 1932 and afterwards this tumor model was
widely used in cancer research (Yoshida 1971). The subline
of Ehrlich ascites tumor we used is Ny Klein which was converted
from solid Ehrlich carcinoma by Klein and Klein (1956) into
the ascites form and used as ,the tetraploid Ehrlich ascites
tumor. Since this tumor cell line is easy to handle and
maintain either in vivo or in vitro and has the advantage of
its ascites nature, it becomes one of the most common tumor
cell lines in cancer research.
Ehrlich ascites tumor cells metabolized glucose to lactic
acid which was then transported out of the tumor cells (Warburg
1956). The glycolytic capacity of the tumor cells may be
responsible for the low glucose concentration( 0.2 mM) found
in the ascites fluid in vitro (Fishman and Baily 1974), although
it may also be attributable in part to a compromised rate of
4glucose delivery by the systemic circulation relative to the
dense cell suspension in the peritoneal cavities (Warburg 1956).
It was found that the aerobic glycolysis in Ehrlich ascites
tumor cells is accompanied with the derangements of phospho-
fructokinase (Lazo and Sols 1979) pyruvate dehydrogenase
complex (Lazo and Sols 1980a) hexokinase (Lazo et al 1978
Gregory and Bose 1979) lactate dehydrogenase (Lazo and Sols
1980b) (Na', K+)- ATPase (Scholnick, Lang and Racker 1973)
and pyruvate kinase (Gosalvez et aZ 1975). Lazo and Sols
(1980b) also found that Ehrlich ascites tumor cells to have a
previously unrecognized isoenzyme of pyruvate dehydrogenase.
These observation were suggested to be responsible for the
aerobic glycolysis in Ehrlich ascites tumor cells, however none
of them can accurately explain its actual role in the mechanism
of aerobic glycolysis in Ehrlich ascites tumor cells.
III. Investigation of glucose carrier by cytochalasin B binding
Cytochalasin B is a mold metabolite and has been shown to
prevent motility and cytokinesis in fibroblastic cells (Carter
1967) by destroying the integrity of the microfilaments in the
contractile ring (Schroeder 1969). Wessel et aZ (1971) has
further found that cytochalasin B can break down the micro-
filaments in several cell types and prevent morphogenesis. In
addition to its effects on cellular morphology and microfilament
structure, cytochalasin B was recently found to be a potent,
reversible inhibitor of sugar uptake in cultured cells
(Kletzien, Perdue and Springer 1972 Czech, Lynn and Lynn 1973).
5It does not prevent the uptake of thymidine, uridine, a-amino-
isobutyric acid or calcium in cells (Kletzien, Perdue and
Springer 1972 Czech, Lynn and Lynn 1973). Two classes of
binding sites for cytochalasin B with different affinities
were found in bovine red blood cells, Hela cells and SV40
transformed mouse fibroblasts (Lin, Santi and Spudich 1974).
Recently, Jung and Rampal (1977) found that the site I of the
three major cytochalasin B binding sites on human erythrocyte
and its membrane preparation is dircetly associated with the
glucose transport carrier. They later found that the site III
was also glucose-sensitive when site II either bound a ligand
or was removed (Pinkofsky et aZ 1978), and the binding
activities of erythrocytes membrane were partially solubilized.
IV. Glucose carrier on erythrocytes and other cell lines
The nature of glucose-sensitive cytochalasin B binding
sites on human erythrocytes were extensively studied. It was
found that this cytochalasin B binding site is responsible for
glucose transport in erythrocytes (Jung and Rampal 1977
Pinkofsky et al 1978). Deves and Krupka (1978) demonstrated
that cytochalasin B can inhibit glucose transport in human
erythrocytes by competing with glucose for the carrier on the
inner surface of the cell membrane, but there is no cytochala-
sin B binding site associated with the outward-facing form of
the carrier. Meanwhile, cytochalasin B binding component of
human erythrocyte monosaccharides transport system has been
purified (Kasahara and Hinkle 1977 Bladwin, Bladwin, Gorga
6and Lienhard 1979). Kasahera and Hinkle (1977) found that all
sugars which inhibit glucose transport can also inhibit the
binding of cytochalasin B to this purified transporter. This
glucose carrier is a glycoprotein with the apparent molecular
weight estimated by SDS PAGE of about 55,000. After the removal
of its carbohydrate moiety, its molecular weight is about
46,000 (Kasahara and Hinkle 1977 Sogin and Hinkle 1978Jung
et aZ 1979 Cuppoletti and Jung 1981). This transporter
molecule was found heterogeneously glycosylated as they showed
a broad zone in SDS PAGE (Gorga, Bladwin and Lienhard 1979).
Sogin and Hinkle (1978) showed that their preparation of red
cell glucose carrier contains 24% acidic amino acid, and 5%
neutral sugars (of which 3% was galactose), 7% glucosamine and
5% sialic acid. This glucose carrier was found to be stereo-
specific that it cannot bind L-glucose (Zoccoli, Bladwin and
Lienhard 1978). Recently reconstitution of purified human
erythrocytes glucose carrier in an artificial membrane
(liposome) was used in the studies of the nature of this
transporter molecule and found that the reconstituted glucose
carrier retained its glucose transport activity and cyto-
chalasin B binding activity (Kasahara and Hinkle 1977 Bladwin,
Gorga and Lienhard 1981 Lundahl et aZ 1981). Most recently,
photoaffinity labelling of glucose carrier with 3H1-cytochalasin
B was successful in human erythrocyte membrane (Carter-Su et aZ
1982 Shanahan 1982). This finding provides a new technique
tool for the study of glucose carrier in other cell lines.
Studies on the glucose carrier of other cell lines are very
7limited. Plagemann and his coworkers (Plagemann et aZ 1981
Graff, Wohlhueter and Plagemann 1981) showed that mammalian
cell lines possess hexose transport system with directional
symmetry but differential mobility of loaded and empty carriers.
Several workers used the tcehnique of cytochalasin B to study
the effect of insulin on adipocytes. They found that insulin
can increase cytochalasin B binding sites as well as glucose
transport activitiy in adipocytes and this increase in glucose
carriers is due to the translocation of the transporter
molecules from microsomal fraction to plasme membrane (Suzuki
and Kono 1980 Karnieli et al 1981 Kono et al 1981 Resh 1982).
Recently, human erythrocytes glucose carrier antibodies
were used to determine the distribution of glucose carriers on
the menbrane of other cell lines (Sogin and Hinkle 1980 a b
Bladwin and Liebllard 1980).
These antibodies can cross-react with the glucose carreirs
of adipocytes (Lienhard et al 1982 Wheeler et al 1982) and
those of normal and Rous sarcoma virus-transformed chick
embryo fibroblasts (Salter et aZ 1982). Based on the above
evidences, it was suggested that there may be structural
similarities shared by the glucose carriers in different cell
lines.
V. Glucose-sensitive cytochalasin B binding sites on Ehrlich
ascites tumor cells
In 1967, Kolber and Lefever (1967) were the first who
demonstrated the evidence for carrier-mediated glucose uptake
8by Ehrlich ascites tumor cells. However, in spite of the
large accumulation of information on the studies of the
nature of glucose carrier on human erythrocytes and other cell
lines, the study on glucose carrier on Ehrlich ascites tumor
cells is scarce. Cuppoletti et al (1981) were the first who
showed that cytochalasin B can competitively inhibit the
carrier-mediated glucose uptake by Ehrlich ascites tumor cells
with an inhibition constant (Ki) of approximately 5 x 10-7 M.
They found that cytochalasin B can bind on Ehrlich ascites
tumor cells with three different degree of affinities, low
affinity with Kd= 1 x 10-6 M, medium affinity with Kd= 2-6
x 10-7 M and high affinity with Kd= 2-6 x 10-8 M. The binding
of cytochalasin B to the medium affinity binding sites can be
completedly inhibited by the addition of glucose and this class
of cytochalasin B binding sites was suggested to be responsible
for the carrier-mediated gluocse uptake which is inhibited by
cytochalasin B, and this binding sites is stereospecific for
D-glucose. This glucose-sensitive cytochalasin B binding site
represents approximately 60% of the total saturable cytochala-
sin B binding sites on Ehrlich ascites tumor cells. Ehrlich
ascites tumor cell is unique among other cell lines in its high
content of this binding site which amounts to more than 20% of
the plasma membrane protein. It is at least 4-fold greater
than that of transformed chicken embryo fibroblasts (Salter
and Weber 1979), that of human erythrocytes (Jung and Rampal
1977) and those of many other animalell lines renorted in
9literatures (Plagemann, Graff and Wohlhueter, 1977). It is of
value to study the role of this high content of glucose-
sensitive cytochalasin B binding sites on Ehrlich ascites
tumor cells.
Based on the finding of Cuppoletti, Mayhew and Jung
(1981), it is reasonable to believe that the glucose-sensitive
cytochalasin B binding sites on the Ehrlich ascites tumor
cells as well as those of other cell lines (Lin, Santi and
Spudich 1974 Jung and Rampal 1977 Pinkofsky et aZ 1978)
are closely related or even identical to the glucose carriers
which are responsible for the carrier-mediated uptake of
glucose.
Since Ehrich ascites tumor cell is characteristic for
its high content of glucose-sensitive cytochalasin B binding
sites, it provides as a convenient source for the isolation,
purification and characterization of this class of glucose-
sensitive cytochalasin B binding sites. Preliminary studies
has been reported by Cuppoletti, Mayhew and Jung (1981) that
this glucose-sensitive cytochalasin B binding site may be a
protein.
Study on glucose-sensitive cytochalasin B binding sites
on Ehrlich ascites tumor cells is very limited. Therefore
it is worthwhile to furhter study its properties especially
its binding specificity. It is of significance to determine
whether the number of glucose-sensitive cytichalasin B binding
sites on Ehrlich ascites tumor cells and other cell lines
share the common structures.
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VI. Anti-tumor effect of methotrexate on Ehrlich ascites tumor
Methotrexate (MTX) is an analogue of the vitamin folic
acid. Folic acid itself is not biologically active and must
be reduced by folate reductase and then dihydrofolate reduc-
tase to dihydrofolic acid and thence to tetrahydrofolic acid,
which accepts 1-carbon fragment from various sources to
generate the folate coenzymes. The latter are utilized as
1-carbon group donors in a variety of reactions, including the
synthesis of the methyl group of thymidylic acid, the insertion
of the C-2 and C-8 atoms of the purine skeleton, and
the (3-carbon of serine (Stokstad and Koch 1-0167).
The biological effects of methotrexate are due entirely
to its inhibition of the reductase (Jukes and Broquist 1963).
Inhibition of the reductase prevents generation of tetrahydro-
folate and ultimately results in a cessation of the reaction
requiring folate coenzymes such as biosynthesis of thymidylic
acid, purines and serine, and-thus the process of DNA synthesis
and cellular replication. Borsa and Whitmore (Borsa and
Whitmore 1969) suggested that methotrexate may have other sites
of action in addition to its inhibition of folate and dihydro-
folate reductase. Thymidylate synthetase and, in the presence
of excess deoxycytidine, the transformylase enzymes involved
in the purine synthesis de novo are probably two such sites.
Methotrexate can also interfere with the ulitization of
existing reduced folates that the competition is not at the
transport level.
Since DNA synthesis and cellular replication is important
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in rapidly proliferating tissue. Active proliferating
tissue such as malignant cells, bone marrow, fetal cells,
dermalepithelium, buccal and intestinal mucosa and cells of
the urinary bladder are in gereral more sensitive to the
effect of methotrexate. Cellular proliferation in malignant
tissue is greater than in most normal tissue and thus metho-
trexate may impair malignant growth more pronouncedly. Hrynuik
(Hrynuik 1972) found that methotrexate suppressed incorporation
of 3H-thymidine into DNA, 3H-uridine into RNA, of 3H-leucine
into protein and killed L5178Y murine lymphoblasts. MTX
arrests the growth of tumor cells also by the induction of a
purineless states in these cells.
Kaminskas and Nussey (1978) found that glycolytic rate
of Ehrlich ascites tumor cells decreased with methotrexate
treatment, adenylate pools and adenylate energy charge were
also decreased in cells isolated in methotrexate containing
medium in vitro. The purineless state was accompained by a
sereve inhibition of ATP regeneration. This suggests that
the major cytotoxic effect of methotrexate appears to be due
to an energy-depleted state.
Ehrlich ascites tumor cells are highly dependent on
glycolysis for their energy metabolism. Other tumor cells and
normal cells which depend mainly on respiration for their
energy metabolism, may be less sensitive to depletion of
adenylate pool and to inhibition of glycolysis by methotrexate
(Kaminskas and Nussey 1978). Transformed fibroblasts (Schwartz
and Johnson 1976), Novikoff rat hepatoma cells (Plagemann and
12
Erbe 1.973) and reticulocytes (Freudenberg and Mager 1971)
tolerate glucose starvation without decreasing their adenylate
pool or the adenylate energy charge unless respiration is
inhibited as well.
Methotrexate can also inhibit the uptake of 2-deoxy-D-
glucose and 3-0-methyl-D-glucose in cultured Ehrlich ascites
tumor cells (Kaminskas 1979) but hexokinase activity was found
not to be affected. Since the administration of methotrexate
can control tumor growth in tumor bearing hosts, it is of
value to investigate whether a similar effect of methotrexate
on glucose uptake of tumor cells can be obtained when Ehrlich
ascites tumor bearing mice are treated with methotrexate
in vivo.
Furthermore, in vivo measurement on the glucose carriers
on tumor cells during Ehrlich ascites tumor development and
MTX treatment are of interest.
VII. Aim of study
2-deoxy-D-glucose uptake by different days old Ehrlich
ascites tumor cells in vivo was studied in order to see
whether there is any change in glucose uptake by the tumor
cells during tumor development. Furthermore, the number of
glucose-sensitive cytochalasin B binding site was also measured
as a parallel study to confirm the results of the glucose
uptake experiments. Since the study on the nature of glucose-
sensitive cytochalasin B binding sites on Ehrlich ascites tumor
cells are relatively limited, and its relationship to glucose
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carrier is not established, therefore the properties of binding
specificity of glucose-sensitive cytochalasin B binding sites
by using other sugars and glucose uptake inhibitors were studied
Based on the results of the above experiments, it is
suggested that glucose uptake as well as the number of
glucose-sensitive cytochalasin B binding site increased
progressively during tumor development in vivo. It is also
shown that the glucose-sensitive cytochalasin B binding sites
are closely related if not identical to the glucose carriers
which are responsible for the transport of glucose in Ehrlich
ascites tumor cells. Therefore the possible factors those may
cause the changes in the number of glucose carrier in Ehrlich
ascites tumor cells during tumor development are also
investigated.
Tumor bearing patients are always hypoglycaemic.
Similarly, the blood level of animals carrying various tumors
have lower value than normal animals (Del Monte and Rossi 1963
Tagi-Zade and Shapot 1971). In Ehrlich ascites tumor bearing
mice, hypoglycemia can also be observed (Pavelic et aZ 1979).
On autopsy of the animals from the experimental group, a direct
correlation was found between the size of the tumor and the
magnitude of the decrease in the blood sugar levels, as well
as an inverse. correlation between this decrement and the amount
of necrose. It appeared that the extent of hypoglycemia
depended on the number of viable cancer cells. A similar
correlation between the magnitude of hypoglycemia and growth of
lymphetic leukemic tumor in mice was observed (Silverstein
14
et aZ 1964).
The glucose level in normal mouse peritoneal fluid and cell
free peritoneal fluid are 95 and 82 mg/100 ml respectively
(Nakamura and Hosoda 1968) which are just slightly lower than
that of normal mice serum glucose concentration (Mallick et al
1968). By contrast, the ascites fluid as well as the cell
free ascites fluid did not contain any detectable glucose
(Chan et aZ 1983). Ehrlich ascites tumor cells also do not
contain detectable intracellular glucose (Nakamura and Hosoda
1968). Relationship between changes of serum glucose and
glucose carrier on tumor cells are also studied.
Since glucose is the major source of energy in Ehrlich
ascites tumor cells (Lazo 1981) and it is obvious that
glucose uptake is important for the growth of Ehrlich ascites
tumor cells. Amos and co-workers (Martineau et aZ 1972) have
showed that the rate of glucose (or 2-deoxy-D-glucose) uptake
by chick fibroblast cultures is governed by the glucose
concentration in the medium during growth. High glucose
concentration during growth seems to repress glucose
transport, whereas low glucose concentration elicits a
derepression effect on this transport system. In addition,
glucose starvation can stimulate the uptake rate of glucose in
chick fibroblasts (Shaw and Amos 1973).
Tumor development can cause a significant drop in the
elevated level of blood glucose and disappearance of glucos-
uria in diabetic patients (Vaissman et at 1964). In alloxan-
induced diabetic rats, Novikoff hepatoma and Walker carcinoma-
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256 development were found to reduce the blood sugar level
(Goranson et aZ 1954 Goranson and Tilser 1955). In alloxan-
induced diabetic mice Ehrlich ascites tumor development can
also decrease the blood glucose level (Pavelic et al 1979).
Based on the above evidences, it is reasonable to suspect
that the decrease in serum glucose of tumor bearing hosts may
be a stimulant of increased glucose uptake rate as well as
increased number of glucose carriers in Ehrlich ascites tumor
cells.
In order to investigate the effect of serum glucose of
Ehrlich ascites tumor bearing mice on the number of glucose
carriers in tumor cells, carrier number in the tumor cells
harvested from mice induced hyperglycemia and hypoglycemia
by injecting streptozotocin (Maclaren et aZ 1980 Bond 1980)
and insulin (Pavelic 1979) respectively are studied.
However it was found that insulin can increase the rate
of glucose uptake in chick embryo fibroblasts and Hela cells
(Shaw and Amos 1973), and the translocation of glucose carriers
from microsomal storage pool to plasma membrane in rat
adipocytes (Suzuki and Kono 1980 Karnceli et al 1981 Kono
et al 1981). In order to clarify the hormonal effects on the
number of glucose carriers in Ehrlich ascites tumor cells,
glucose carrier number in the tumor cells after the direct
incubation with insulin are studied. Furthermore, hypoglycemia
developed in Ehrlich ascites tumor bearing mice may induce
hyperplasia of the adrenal cortex and hypersecretion of
glucocorticoids. The final phase of tumor development was
16
reported to be characterized by emaciation of the gland, and
depletion of the glucocorticoids reserve (Lichter and Sirett
1968 Kawai et al 1969). Therefore, the direct effect of the
hormones on the number of glucose carriers in Ehrlich ascites
tumor cells is of interest to be investigated.
On the other hand, the effect of glucose concentration
on glucose carriers are also studied by using in vitro
incubation. 7 day-old Ehrlich ascites tumor cells were
incubated in two different glucose concentration and the change
in glucose carriers during incubation were recorded. The
result of this experiment can serve as an additional evidence
to further confirm the relationship between glucose level and
the number of glucose carriers.
As MTX can decrease the growth of many tumor cell lines
including Ehrlich ascites tumor cells, and the uptake of
2-deoxy-D-glucose by Ehrlich ascites tumor cells is also
inhibited by MTX in vitro (Kaminskas 1979). It is of interest
to study whether there is a similar effect of MTX on glucose
uptake by Ehrlich ascites tumor in vivo. Therefore in the
final part of the studies, effect of MTX on glucose uptake
by the tumor cells is examined. Its effect on the number
of glucose carrier in the tumor cells is also studied as a
parallel study to the above mentioned experiment.
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Ml'-TERIALS AND METHODS
Mat- Pri a 1
The suppliers of the materials are shown in table:
Table: Materials and Suppliers
Materials Suppliers
Antibiotics- antimycotics Gibco (Grand Island Biological
(penicillin 10,000 U/ml ComDanv)
fungizone 25 mcg/ml
streptomycin 10,000 mcg/ml)





3H-cytochalasin B New England Nuclear
(7.2 Ci/rnnol)
2-Deoxy-D-Glucose Sigma
2-Deoxy-D-j H-glucose New England Nuclear
(37.3 Ci/mmol)
Diethylstilbestrol Sigma
D-(-) Fructose British Drug House
L-(-) Fucose Sigma




D-(-) Glucose British Drug House
L-Glucose Sigma
Glucose Kit-(Kit 510-DA) Sigma
Hepes Sigma
Insulin Sigma
Lactose British Drug House
Maltose Ajax




Protamine zinc insulin Weddle Pharmaceuticals Ltd.
( U.K.)




I. Maintenance of Ehrlich ascites tumor cell line
Ehrlich ascites tumor, Ny Klein cell type, was maintained
by intraperitoneally implantation in albino mice (ICR strain).
Mice bearing 7 day-old tumors were killed by cervical dislocation.
The pooled tumor cells were washed five or more times with half
isotonic saline to remove the blood cells completedly (Wu and
Racker 1959) and harvested by centrifugation at 800xg for 90
seconds at room temperature in an IEC table-top clinical centri-
fuge. The packed cells were then resuspended in phosphate-
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buffered saline (PBS), pH 7.4. Mice weighing 30-35 gm were
inoculated intraperitoneally with 107 washed Ehrlich ascites
tumor cells in 0.2 nil PBS. Cell count was determined with a
haemocytometer.
II. Uptake of 2-deoxy-D-glucose by Ehrlich ascites tumor cells
To determine the rate of 2-deoxy-D-glucose uptake by
Ehrlich ascites cells, the procedure of Kaminskas (Kaminskas
1979) was used with minor modification. Mice were inoculated
with Ehrlich ascites tumor cells on day 0. Tumor bearing mice
were killed on days 2, 4, 5, 7, 9 and 11. The harvested tumor
cells were pooled and washed free of blood cells and finally
resuspended in PBS enriched with 3.2 mM CaCl2, 1.5 mM MgSO4,
6.1 mM pyruvate, 6.7 mI1 fumate and 6.1 mM glutamate, pH 7.4
(incubation buffer). Tumor cells from the group of day 2 were
harvested from 40 mice while those of day 4 were harvested from
20 mice. Cell concentration was adjusted to 108/ml in incuba-
tion buffer. Aliquots (1 ml) of cell suspension were placed
in stoppered flasks and equilibrated to 370 C in a shaking water
bath for 15 minutes. One ml of 2-deoxy-D-3H-glucose (1iCi/umol)
was then added to give final concentrations of 0.25, 0.33, 0.50,
1.00 and 2.50 mM. The content of the flasks were rapidly mixed
and the incubation continued at 370 C. Samples of 200 pl were
removed after 15, 35, 60, 90, 120, 150 and 180 seconds and
added with rapid mixing to test-tubes containing 3 ml of ice-
cold PBS supplemented with 15 mM 2-deoxy-D-glucose. Cells were
collected by centrifugation at 800xg for 90 seconds at 40C in a
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Beckman J2-21 refrigerated centrifuge. The supernatant was
removed by aspiration and the packed cells were washed once
again with 3 ml of the above buffer. Cell lysis was accomplished
by adding 2 ml of distilled water and mixing with Vortex mixer.
One ml of lysate were then mixed with 7 ml of a Triton X-100-
toluene scintillant (Patterson and Greene 1965) and counted in
a Beckman LS 7000 liquid scintillation counter.
The uptake of 2-deoxy-D-glucose were calculated from counts
per minute of the samples against a standard curve. The inital
rate of uptake (Vo) of 2-deoxy-D-glucose at each sugar concentra-
tion used was measured graphically. The kinetic parameters of
the uptake process, namely, the maximal uptake rate (Vmax) and
apparently half-saturation constant (KM) were determinated by
correlating Vo with sugar concentration according to the double-
reciprocal formulation of Lineweaver and Burk after correction
for non-specific diffusion (unsaturable diffusion) (Renner,
Plagemann and Bernlohr 1972 Plagemann and Richey 1974).
III. Glucose-sensitive cytochalasin B binding sites on Ehrlich
ascites tumor cells
Equilibrium binding of cytochalasin B to Ehrlich ascites
tumor cells were performed according to the methods which were
commonly used for the measurement of the glucose carriers on
red blood cells (Jung and Rampal 1977 Pinkofsky et aZ 1978
Cuppoletti, Mayhew and Jung 1981) with slight modifications.
Ehrlich ascites tumor cells were obtained and resuspended in
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PBS as described. Cell concentration were adjusted to 2 x
10 7/ ml. For measuring the total cytochalasin B binding 1 ml
of incubation mixture contained 107 cells, 0.02 pCi 3H-cyto-
ch alasin B and 2 x 10-9- 5 x 10-6 M cytochalasin B. To assess
the glucose-insensitive binding, D-glucose was also added to the
incubation mixture to a final concentration of 500 mM. The
mixtures were allowed to equilibrate for 20 minutes at room
temperature in a Thermolyne speci-mix (Thermolyne U.S.A.).
Bound ligand was separated from free ligand by centrifugation
at 25,000xg for 20 minutes at 4 0 C in a Beckman J2-21 refri-
gerated centrifuge (Beckman U.S.A.). An aliquot (0.5 ml) of
the supernatant was removed and its radioactivity was counted.
The test-tubes were then drained and the residual supernatant
was carefully decanted and wiped with cotton swabs. 1 ml of
distilled water was added to lyse the tumor cells, after which
0.5 ml of the cell lysate was used for radioactivity measure-
ment.
The cytochalasin B bound was calculated as percentage of
total. The difference in cytochalasin B binding between in the
absence (total binding) and presence (glucose-insensitive bind-
ing) of 500 mM D-glusoce is the glucose-sensitive binding of
cytochalasin B on Ehrlich ascites tumor cells.
Inasmuch as the glucose-sensitive cytochalasin B binding
sites have been shown to represent the functional glucose
carriers in various cell types studied (Karnieli et aZ 1981
Coppoletti, Mayhew and Jung 1981 Sogin and Hinkle 1980 a Suzuki
and Kono 1980 Jung and Rampal 1977 Lin, Santi and Spudich
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1974 Pinkofsky et al 1978), the putative glucose carriers on
Ehrlich ascites tumor cells were determined by Scarchard
analysis of the glucose-sensitive cytochalasin B binding on
the tumor cells.
IV. Glucose level in the serum and ascitic fluid of tumor bearing
mice
Glucose level in the sera and ascites fluid of tumor bearing
and normal mice were determined by using Glucose Kit supplied
from Sigma Chemical Company (Kit 510-DA). Blood samples were
obtained from mice after overnight fasting. Cell-free ascites
fluid was obtained by centrifugation the peritoneal exudate from
tumor bearing mice at 800xg for 5 minutes. Protein of the samples
(ascites fluid and sera) were removed with the addition of half
volume of 0.3 N barium hydroxide and zinc sulfate. 5.0 ml
combined enzyme-color reagent (glucose oxidase and o-dianisidine
dihydrochl.oride) solution were added to deproteinized samples.
All samples were incubated at 37° C for 30 minutes and then the
absorbance of the samples at 440 nm was determined. The
glucose level of the samples were calculated from their absorbance
at 440 nm against glucose standard curve.
V. Effect of methotrexate (MTX) on glucose uptake and glucose
carrier on Ehrlich ascites tumor cells
Mice were inoculated with 107 ascites tumor cells harvested
from 7 day-old tumor in 0.2 ml PBS on day 0 as described. The
effect of MTX was examined in groups of at least ten mice each.
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In the test groups, MTX (0.4 mg/Kg body weight) in normal saline
was administered on days 2, 4 and 6 (group A) or on days 4, 5 and
6 (group B) post implantation. In the control group, only
saline was injected. On day 7, all groups of mice were killed
and the tumor cells were harvested and washed. The glucose up-
take and glucose carriers on Ehrlich ascites tumor cells were
then determined.
VI. Specificity of the glucose carriers on Ehrlich ascites tumor cells
In these experiments, 7 day-old tumor cells were used.
Equilibrium binding of cytochalasin B was performed in the presence
and absence of 500 mM of D-(+) mannose, D-(+) galactose, D-(-)
fructose, L-glucose, 3-0-methyl-D-glucose, 2-deoxy-D-glucose,
D-(-) arabinose, glucosamine, L-(-) fucose, maltose, lactose and
sucrose and two glucose uptake inhibitors, phloretin and diethyl-
stilbestrol, at the concentration of 5 x 10-5 M and I x 10-4 M re-
spectively. Binding data were analysed by Scathard plots as for
D-(+)-glucose.
VII. Effects of diabetes on glucose carriers on Ehrlich ascites tumor
cells in vivo
Tumor bearing mice weighing 30-35 gm were devided into four
groups with 10 mice in'each group: insulin treated, strepto-
zotocin-induced diabetic, diabetes with insulin treatment and
control groups.
In insulin treated group, 4 IU/mouse of insulin were sub-
cutaneously injected into the mice 18 hours before inoculation
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of 107 tumor cells. Insulin was then injected every 36 hours
post implantation. The dosage of insulin was 4 IU/mouse in the
first and second injection, 3 IU/mouse in the third injection,
2 IU/mouse in the fourth injection, and 1 IU/mouse in the fifth
injection.
In streptozotocin-induced diabetic group, streptozotocin
(200 mg/Kg body weight) in citrate buffer, pH 4.2 was intra-
peritoneally injected into the mice three days before the
inoculation of tumor cells. Blood glucose of streptozotocin
treated mice was determined prior to the inoculation of 107
tumor cells to ensure the diabetogenic effect of streptozotocin
(Junod et aZ 1967 Brosky and Logothetpoulos 1969 Renold et aZ
1974).
In the group of diabetes with insulin treatment, the mice
were induced diabetic with streptozotocin as described above.
Blood glucose was determined prior to the injection of insulin.
The inoculation of 107 tumor cells was performed 18 hours after
the first injection of insulin. The dosage and intervals of
insulin injections were same as described in the insulin treated
group.
In the control group, only normal saline was injected into
the Ehrlich ascites tumor bearing mice inoculated with 107 cells.
Serum glucose of the four groups of mice was determined every
two days during the development of tumor cells. Blood samples
were obtained after 4 hours of fasting of the mice.
All groups of mice were killed seven days after tumor
inoculation by cervical dislocation. Tumor cells were harvested,
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washed and the glucose carriers on the tumor cells were
determined by methods as described above.
VIII. Hormonal effect on glucose carriers on Ehrlich ascites tumor
cells in vitro
Tumor cells were harvested from mice bearing 7 day-old
tumors. After the removal of the blood cells by half-isotonic
saline, tumor cells were resuspended in PBS supplemented with
3.2 mM CaCl2, 1.5 nM MgSO4, 6.1 mM pyruvate, 6.7 mM fumarate,
6.1 mM glutmate and 0.56 mM glucose. Different hormones were
added to the cell suspension to examine their effects on the
number of glucose carriers in cells. The tumor cells were
incubated at 370 C for 60 minutes in the presence or absence of
different hormones. Cell concentration in incubation buffer is
2 x 107/ml. The concentration of insulin were 0.5 IU/ml and
0.05 IU/ml designated as high and low dosage of insulin
respectively, that of glucagon was 5 x 10-3 mg/ml and those of
corticosterone and cortisone were 25 x 10-3 mg/ml. These
hormonal concentrations are essentially comparable with those
in the study of hormonal effects on the glucose uptake by
erythrocytes, chick fibroblasts and Hela cells (Lacko et aZ
1975 Shaw and Amos 1973 Lacko, Wittle and Lacko 1977). After
60 minutes of incubation, the tumor cells were harvested by
centrifugation in an IEC table-top clinical centrifuge and
washed twice with PBS at room temperature. Then the washed
cells were assayed for glucose carriers.
26
IX. Effect of glucose concentration on glucose carriers on Ehrlich
ascites tumor cells in vitro
Tumor cells were harvested from mice bearing 7 day-old
tumors. After the removal of the blood cells by half-isotonic
saline, tumor cells were resuspended in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 5% heat-inactivated calf
serum, 3.5% cell free ascites fluid, antibiotics-antimycotics
mixture giving a final concentration of penicillin to 100 U/ml,
fungizone to 0.25 mcg/ml and streptomycin to 100 mcg/ml.
Glucose was then added to give final concentrations of 1.9 and
5.5 mg/ml. The cell suspensions were mixed with glucose and
incubated at 370 C. The cell concentration was adjusted to
4 x 106/ml. Aliquots of cell suspension were taken out in
different time intervals. Cells were harvested by centrifuga-
tion and washed twice with PBS at room temperature. The washed
tumor cells were then assayed for glucose carriers. The super-
natant in the aliquots were determined for glucose concentration.
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RESULTS
I. Growth characteristics of Ehrlich ascites tumor cells in mice
Before experiments with Ehrlich ascites tumor cells were
performed, the growth characteristics of Ehrlich ascites tumor
cells in vivo have been studied. Mice were inoculated intra-
peritoneally with 107 Ehrlich ascites tumor cells as described
in Materials and Methods on day 0. Fig. 1A shows the growth
curve of Ehrlich ascites tumor cells in vivo. In the first two
days post implantation, the tumor cells grew slowly. This
period is designated as latency period as originally suggested
by Klein and Revesz (1953). Between day 2 and day 7, tumor
cells grew most rapidly while in the period of day 7 to day 11,
tumor cell number increased slowly and seemed to be level off.
This last part of the growth curve is designated as terminal
phase (Klein and Revesz 1953). Although the cell number
increased slowly in terminal phase, the volume of ascites fluid
increased tremendously in this phase (Fig. 1B) leading to a
slight decrease in cell concentration of tumor cell in ascites
fluid (Fig. 1C).
Fig. 2 shows the change in net body weight after exhaustive
drainage of tumor cells during tumor development. Net body
weight of tumor bearing mice increases significantly comparing
to that of day 0 during tumor development and reaches a peak
value of 36.8 gm on day 4 (p 0.05) and then decreases signi-
ficantly (p 0.01) afterwards. The decrease in net body weight
of tumor bearing mice may be due to cancer cachexia which is
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Fig. 1 Growth characteristics of Ehrlich ascites tumor bearing mice
during tumour development. Tumor bearing mice were inoculated
with 107 cells on day 0. Total tumor cell number, volume of
ascites fluid and cell concentration in ascites fluid were
determined on indicated days post transplanatation. Values
are presented as mean± S.E.M. for three experimental groups.
A. Growth curve (semi-log) of Ehrlich asictes tumor cells in
mice. Cells were harvested from mice and counted with
haemocytometer.
B. Volume of total ascites fluid. Ascites fluid was drained
from tumor bearing mice and mueasured.








Fig. 2 Changes in net body weight of Ehrlich ascites tumor bearing
mice. Mice were inoculated with 107 tumor cells on day 0.
Mice were weighed after the exhaustive drainage of tumor
cells and ascites fluid from their peritoneal cavities on
indicated days post transplantation. Values are presented




commonly found in tumor bearing animals (Shapot 1972), however,
the reason of the increase in net body weight of tumor bearing
mice in the early period is not understood.
I1 Changes in 2-deoxy-D-glucose uptake rate of Ehrlich ascites
tumor cells during tumor development in vivo
Uptake of 2-deoxy-D-glucose by Ehrlich ascites tumor cells
during tumor development was studied. Fig. 3A shows a typical
time curve of incorporation of 2-deoxy-D-3H-glucose when 7 day-
old tumor cells were exposed to various concentrarion of 2-deoxy-
D-gucose. The rate of uptake was rapid in the first 10 seconds
it then fell gradually with time. When the initial rate was
plotted against the concentration of 2-deoxy-D-glucose (Fig. 3B,
curve A), considerable deviation from normal Michaelis-Menten
kinetics was seen. Similar observation has been made with the
transport of 2-deoxy-D-glucose (Renner, Plagemann and Bernlohr
1972) and nucleosides (Plagemann 1971) in Novikoff rat hepatoma
cells and it has been suggested that at high enough concentra-
tion, 2-deoxy-D-glucose can enter the cells at a significant
rate by simple diffusion (unsaturable component). The extent of
the diffusion-mediated uptake can be estimated graphically by
drawing a line (Fig. 3B, curve B) through the origin and
parallel to the linear portion of the uptake curve (Renner,
Plagemann and Bernlohr 1972 Plagemann and Richey 1974). The
uptake rate due to the transport reaction was obtained by sub-
tracting the estimated diffusion rate due to unsaturable com-
ponent from the overall rate (Fig. 3B, curve C). The corrected
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rates showed that the uptake of 2-deoxy-D-glucose by Ehrlich
ascites tumor cells is a saturable process, and follows Michaeli_s-
Menten kinetics. Lineweaver-Burk plot of the facilitated uptake
rate (Fig. 3C) of 2-deoxy-D-glucose by 7 day-old Ehrlich ascites
.tumor cells yielded a typical best-fit straight line by linear
regression from which the kinetic parameters, Vmax and KM,
representing respectively the maximal uptake rate and apparent
half-saturation constant of the uptake process can be determined.
Fig. 4 shows that the values of Vmax increased linearly with
the progress of tumor growth, rising from 66 nmol/min/5x106 cell
on day 2 to 242 nmol/min/5x106 cell on day 11 post implantation
of Ehrlich ascites tumor cells. By contrast the values of KM
remained unchanged throughout the course of the experiment at
about 0.6 mM. These observation can be interpreted to indicate
that the nature of the hexose carrier molecules appeared to be
relatively unaffected, the transport activity of such molecules
increased progressively with the tumor development. The
increase in transport activity may be due to the increase in the
number of the carrier molecules or alternatively, the turnover
rate of the glucose transport system may have increased as the
tumor grows. To differentiate between these two possibilities,
the equilibrium binding of cytochalasin B on Ehrlich ascites
tumor cells was studied.
Fig. 3 Representative experiment of the uptake of 2-deoxy-D-glucose
by 7 day-old Ehrlich ascites tumor cells.
A. Initial rate of uptake by 7 day-old tumor cells at various
final concentrations of 2-deoxy-D-glucose; 0.25 mM (A- A);
0. 33 mM (0- 0); 0.5 mM (A- A); 1.0 mM( O- O); 2.5 mM
( © - © ) .
B. Initial rates of 2-deoxy-D-glucose uptake by 7 day-old
tumor cells as a function of substrate concentrations.
Total uptake, determined graphically from Fig. 3A was
used to construct curve A (O-O). The rate of simple
diffusion (curve B) was determined by drawing a line
through the origin parallel to the linear position of
curve A (Renner et at., 1972). The rate of uptake due
to facilitated diffusion(©-@) was determined by
subtracting these values from the rate of total uptake.
It was seen that the facilitated uptake process follows
Michaelic-Menten kinetics.
C. The Lineweaver-Burk plot of facilitated diffusion
determined in Fig. 3B. The kinetic parameters, Vmax
and Km were obtained as 172 nmolmin5 x lO3 cell and
0.83 mM res pectiveiy.
FIGURE 3
TIME (OOC) [DEOXYOLUCOSE] (mlvl)
(2-DEOXY-D-GLUCOSE)-1 (mM-1)
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Fig. 4 Changes in Vmax (0-0) and Km (0-0) for uptake of 2-deoxy-
D-glucose during tumor development. Values are presented as
mean± S.E.M. for triplicate determinations in two separate
experiments. Statistical analysis for significance of
difference of Vmax on different days post transplantation
relative to data of day 2 was performed using student t-test.
P values of days 4, 5, 7, 9 and 11 for the significance of
difference were 0.001. Km values on different days post




III. Glucose-sensitive cytochalasin B binding site on Ehrlich ascites
tumor cells during tumor development
Fig. 5A shows the results of a representative experiment
using cells from 7 day-old tumors. The presence of 500 mM D-
glucose in the incubation medium inhibited the binding of
cytochalasin B in a competitive manner. This glucose-sensitive
binding site for cytochalasin B, comprising approximately 60%
of the total cytochalasin B binding sites, has been identified
as the glucose transporter in several cell lines including
cultured Ehrlich ascites tumor cells (Pinkofsky, Rampal, Cowden
Jung 1978 Karnieli et al 1981 Sogin and Hinkle 1980 Suzuki
and Kono 1980 Lin, Santi and Spudick 1974 Cuppoletti, Mayhew
and Jung 1981). When the difference in cytochalasin B bound in the
presence of 500 mM D-glucose and the absence of D-glucose from
Fig. 5A was analysed by the Scatchard plot, a best-fit linear
plot was obtained by linear regression (Fig. 5B), from which it
was estimated that for 7 day-old tumor cells, the density of
glucose-sensitive cytochalasin B binding site (Bo) was 215 pmol/
107 cell the dissociation constant (K d) was 2.7 x 10-7 M.
Fig. 6 shows that as the tumor developed the number of glucose-
sensitive cytochalasin B binding site (Bo) increased progres-
sively. When compared with the Bo value for 2 day-old tumor
cells, the difference was highly significant (p 0.001). The
apparent dissociation constant (Kd), however, remained
unchanged.
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Fig. 5 Representative experiment on determination of glucose-
sensitive cytochalasin B binding sites on 7 day-old Ehrlich
ascites tumor cells.
A. Representative experiment showing the binding of
cytochalasin B by Ehrlich ascites tumor cells harvested
from 7 day-old tumors as a function of ligand concentrat-
ions. Cytochalasin B bound was calculated as percent of
total. Percentages of cytochalasin B bound in the
absence (A -,A) and in the presence (0- 0) of 500 tint D-
glucose are shown. The difference represents the D-
glucose-sensitive portion.
B. Scatchard analysis of the D-glucose-sensitive binding
of cytochalasin B to Ehrlich ascites tumor cells
determined from Fig. 5A. Control data from Fig. 5A were
used to calculate the bound and free ligand. The line
was the best fit according to linear least squares
analysis. The binding parameters, total binding site
(Bo) and dissociation constant (Kd) for D-glucose-sensitive
cytochalasin B binding site on Ehrlich ascites tumor








Fig. 6 Changes in Bo (Q- 0) and Kd (0- 0) values for D-giucose-
sensitive binding of cytochalasin B during tumor development.
Values are presented as mean± S.E.M. for three separate
experiments. Statistical analysis for significance of
difference of Bo on different days post transplantation
relative to day 2 value was performed using the Student
t-test.*, P value for the significance of different 0.01
**, P value for the significance of difference 0.001.




IV. Correlation between glucose uptake rate and glucose-sensitive
cytochalasin B binding site on Ehrlich ascites tumor cells
during tumor development
Since both glucose uptake rate and glucose-sensitive
cytochalasin B binding site increased progressively during
tumor development (Fig. 4 and Fig. 6), it is of value to find
out the correlation between them. Fig. 7 shows a plot of
maximal glucose uptake rate (Vmax) versus the number of glucose-
sensitive cytochalasin B binding site (Bo) in the Ehrlich ascites
tumor cells on different days post implantation during tumor
development in mice. A best-fit straight line was obtained by
linear regression with the correlation coefficient greater than
0.976. From this result, glucose-sensitive cytochalasin B
binding site is proven to be a good index in representing the
glucose uptake activity of the tumor cells. Therefore in the
following experiments, only the determination on the number of
glucose-sensitive cytochalasin B. binding site were studied.
In addition to the findings of the researches working on
the glucose transporter in various cell lines including Ehrlich
ascites tumor cell (Pinkofsky et aZ 1978 Karbieli
et aZ 1981 Sogin and Hinkle 1980 Suzuki and Kono 1980 Lin,
Santi and Spudick 1974 Cuppoletti, Mayhew and Jung 1981), our
results also confirm the fact that glucose-sensitive cytochalasin
B binding site is very closely related, if not identical to the
glucose carrier of the cell lines. The increase in number of
glucose carrier sufficiently accounted for the elevated rate of
glucose uptake associated with tumor development.
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Fig. 7 A plot of glucose uptake rate (Vmax) and the corresponding
D-glucose-sensitive cytochalasin B binding site (Bo) on
Ehrlich ascites tumor cells on indicated days during tumor
development. Values are presented as mean± S.E.M. for three
experiments. The line was the best fit according to linear





V. Specificity of glucose carrier on Ehrlich ascites tumor cells
Since a final concentration of 500 mM D-glucose was added
to the incubation mixture to displace the cytochalasin B bound
on the tumor cells, it is of value to investigate whether this
concentration of D-glucose may affect the glucose carrier during
the period of equilibrium binding of the ligands to the tumor
cells. The tumor cells were incubated with PBS supplemented
with 500 mM D-glucose at room temperature in a Thermolyne speci-
mixer. Aliquots of the cell suspension were taken out at 0,
20 and 55 minutes after incubation. The tumor cells were
harvested by centrifugation and washed twice with PBS. The
washed tumor cells were then tested for glucose carrier. Table
1 shows that the number of glucose carrier (Bo) and the dis-
sociation constant (Kd) of the tumor cells remained unchanged
throughout the incubation with 500 mM D-glucose at different
time intervals.
Cytochalasin B binding in the presence of other sugars and
agents known to inhibit D-glucose transport was also examined
by using 7 day-old tumor cells. Fig. 8A shows the binding curve
of cytochalasin B in the presence and absence of 500 mM 2-deoxy-
D-glucose which are comparable to that when D-glucose was added.
The difference of cytochalasin B bound between the presence and
absence of 500 mM 2-deoxy-D-glucose from Fig. 8A was similarly
analysed by Scatchard plot. A best-fit linear plot was also
obtained by linear regression (Fig. 8B). This plot represents
2-deoxy-D-glucose-sensitive cytochalasin B binding site on
Ehrlich ascites tumor cells. It was estimated that the Bo was
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about 218 pmol/10' cell and Kd value was 2.31 x 10' M. Fig. 9A
and 9B show the cytochalasin B binding in the presence and absence
of 500 mM 3-0-methyl-D-glucose as well as Scatchard plot of 3-
0-methyl-D-glucose-sensitive cytochalasin B binding site. The
values of Bo and Kd estimated from Scatchard plot are 205 pmol/
107 cell and 2.24 x 10-7 M respectively. Similarly, the results
of mannose, galactose, maltose are shown in Fig. 10A and lOB
11A and 11B and 12A and 12B respectively. The values of Bo and
K d for mannose are 144 pmol/107 cell and 1.53 x 10-7 M respec-
tively. The values of Bo and K d for galactose are 149 pmol/107
cell and 1.99 x 10-7 M respectively, and those for maltose are
153 pmol/107 cell and 2.00 x 10-7 M respectively. The results
of two D-glucose uptake inhibitors, phloretin (5 x 10-5 M) and
diethylstilbestrol (1 x 10-4 M), are shown in Fig. 13A and 13B
and Fig. 14A and 14B respectively. The values of Bo and Kd for
phloretin are 215 pmol/107cell and 2.30 x 10-7 M respectively
and those for diethylstilbestrol are 139 pmol/10 7 cell and
4.00 x 10-7 M respectively. However, when L-glucose was added,
the binding curves of cytochalasin B remained unchanged dis-
regarding the presence and absence of 500 mM L-glucose (Fig. 15).
It is evident from Fig. 15 that L-glucose cannot displace cyto-
chalasin B from its binding sites and therefore no Scatchard
plot can be obtained. Similar binding curves of cytochalasin B
with or without the addition of D-glucosamine, D-fructose, L-
fucose, D-arabinose, sucrose and lactose are shown in Fig. 16,
17, 18, 19, 20 and 21 respectively. No displacement of cyto-
chalasin B by these sugars could be observed. The specificity
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TABLE 1. APPARENT DISSOCIATION CONSTANT (Kd) AND NUMBER OF GLUCOSE CARRIER (Bo) IN
EHRLICH ASCITES TUMOR CELLS AFTER INCUBATION WITH 500 mM D-GLUCOSEa
Number of glucose carrier Apparent dissociation constantTime after incubation with





a. Cells from 7 day-old tumors were used. The difference in binding in the presence and in the
absence of 500 mM D-glucose was analysed by Scatchard plot. Numbers represent the mean values
of triplicate sample determination.
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Fig. 8 Capacity of Ehrlich ascites tumor cells to bind cytochalasin
B in the presence of 2-deoxy-D-glucose.
A. Binding curves of cytochalasin B by 7 day-old Ehrlich
ascites tumor cells as a function of 2-deoxy-D-glucose
concentration. Percentage of cytochalasin B bound in
the absence(O-O) and in the presence (0- O) of 500 mM
2-deoxy-D-glucose are shown. The difference represents
the 2-deoxy-D-glucose-sensitive portion.
B. Scatchard analysis of the 2-deoxy-D-glucose-sensitive
binding of cytochalasin B to 7 day-old Ehrlich ascites
tumor cells determined from Fig. 8A. Control data from
Fig. 8A were used to calculate the bound and free
ligand. The line was the best fit according to linear
least squares analysis. Total binding site (Bo) and
dissociation constant (Kd) for 2-deoxy-D-glucose-sensitive
cytochalasin B binding site on Ehrlich tumor cells were







Fig. 9- Fig. 14
Capacity of 7 day-old Ehrlich ascites tumor cells to bind
cytochalasin B in the presence of various sugars and two
glucose uptake inhibitors, phloretin (5 x 10-5 M) and
diethylstilbestrol (1 x 10- M):
A. Binding curve of cytochalasin B by 7 day-old Ehrlich
ascites tumor cells as a function of ligand concnetration.
B. Scatchard analysis of the sugars/glucose uptake inhibitors-
sensitive binding of cytochalasin B to 7 day-old Ehrlich
ascites tumor cells determined from A part of the figure.
Control data from A part of the figure were used to
calculate the bound and free ligand. The lines were the
best fit according to linear least squares analysis.
Total binding site (Bo) and dissociation constnat (Kd)
for various sugars/glucose uptake inhibitors-sensitive
cytochalasin B binding site on Ehrlich asictes tumor
cells can thus be determined.
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Fig. 9
A. Binding curves of cytochalasin B in the absence of (0- 0)
and in the presence (0- 0) of 500 mM 3-0-methyl-D-glucose.
B. Scatchard analysis of 3-0-methyl-D-glucose-sensitive
binding of cytochalasin B to Ehrlich ascites tumor cells
determined from Fig. 9A
Fig. 10
A. Binding curves of cytochalasin B in the absence of
and in the presence(-) of 500 mM D-mannose.
B. Scatchard analysis of D-mannose-sensitive cytochalasin B bind-
ing to Ehrlich ascites tumor cells determined from Fig. 1OA.
Fig. 11
A. Binding curves of cytochalasin B in the absence of
and in the presence (0- 0) of 500 mM D-galactose.
B. Scatchard analysis of D-galactose-sensitive cytochalasin B
binding to Ehrlich ascites tumor cells determined from
Fig. 11A.
FIGURE 9A












A. Binding curves of cytochalasin B in the absence(®-®)
and in the presence (O-O) of 500 mM maltose.
B. Scatchard analysis of maltose-sensitive binding of
cytochalasin B to Ehrlich ascites tumor cells determined
from Fig. 12A.
Fig. 13
A. Binding curves of cytochalasin B in the absence(©-©)
and in the presence (O- O) of 5 x 10 M phloretin.
B. Scatchard analysis of phloretin-sensitive binding of
cytochalasin B to Ehrlich ascites tumor cells determined
from Fig. 13A.
Fig. 14
A. Binding curves of cytochalasin B in the absence((§-®) and
in the presence (O- O) of 1 x 10 M diethylstilbestrol.
B. Scatchard analysis of diethylstilbestrol-sensitive binding
of cytochalasin B to Ehrlich ascites tumor cells determined
for Fig. 14A.
FIGURE 12A











Fig. 15 Capacity of Ehrlich ascites tumor cells to bind cytochalasin
B in the presence of L-glucose. The binding curves of cyto
chalasin B by 7 day-old tumor cells as a function of ligand
concentration. Percentage of cytochalsin B bound in the
absence() and in the presence (it- of 500 mM
L-glucose are shown. There is essentially no difference
between these two curves. Therefore no L-glucose-sensitive
portion of cytochalasin B binding and thus no Scatchard
analysis can be constructed.
FIGURE 15
CB COND. (10-6 M)
Fig. 16- Fig. 21
Capacity of Ehrlich ascites tumor cells to bind cytochalasin
B in various sugars. The binding curve of cytochalasin B
by 7 day-old Ehrlich ascites tumor cells as a function of
ligand concentration. Since these sugars cannot displace
cytochalasin B from its binding sites, no Scatchard analysis
of the sugars-sensitive cytochalasin B binding site can be
constructed.
Fig. 16 Binding curves of cytochalasin B in the absence (r-V) and
in the presence of 500 mM D-glucosamine. This is
essentially no difference between these two binding curves.
Fig. 17 Binding curves of cytochalasin B in the absence and
in the presence of 500 mM L-fucose. There is
essentially no difference between these two binding curves.
Fig. 18 Binding curves of cytochalasin B in the absence and
in the presence of 500 mM D-fructose. The difference
between these two binding curves is small and causes
difficulties in constructing Scatchard analysis. Therefore
fructose is regarded as a sugar which cannot displace cyto¬
chalasin B from its binding sites.
FIGURE 16
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Fig. 19 Binding curves of the cytochalasin B in the absence
(-) and in the presence of 500 mM D-arabinose.
There is essentially no difference between these two binding
curves.
Fig. 20 Binding curves of cytochalasin B in the absence
and in the presence (iV-lV) of 500mM sucrose. There is
essentially no difference between these two binding curves.
Fig. 21 Binding curves of cytochalasin B in the absence
and in the presence (iV-iV) of 500 mM lactose. There is
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FIGURE 21
CB CONC. (10-6 M)
TABLE 2. APPARENT DISSOCIATION CONSTANT (Kd) AND NUMBER
OF BINDING SITE (Bo) FOR CYTOCHALASIN B ON
EHRLICH ASCITES TUMOR CELLS3
LIGANDSb COMPETITIVITYc Bo Kd



































a. D-glucose- and ligand-reversible binding of cytochalasin B
was measured as described in the text. Cells from 7 day-old
tumors were used. The difference in the binding in the
presence and in the absence of competing ligands was analysed
by Scatchard plot. Numbers are presented as the mean values
of triplicate sample determination.
b. The final sugar concentrations were 500 mM, those of phloretin
-5 -4
and diethylstilbestrol were respectively 5 x 10 M and 10 M.
c. Ligands which cannot displace cytochalasin B from glucose
carriers are regarded as no competitivity with cytochalasin B
in the binding to glucose carriers.
81
of the glucose.carrier are summarized in Table 2. The
specificity of the glucose carrier is rather high, only two D-
glucose derivatives, 2-deoxy-D-glucose and 3-0-methyl-D-glucose
can substitute D-glucose and completedly displace cytochalasin
B from the glucose carrier. Another two hexose, mannose and
galactose, having very similar structures with D-glucose can
only partially displace cytochalasin B from the glucose carrier.
On the other hand, among the two D-glucose uptake inhibitors,
phloretin can completedly while diethylstilbestrol can only
partially displace cytochalasin B from the glucose carrier.
However the dimer of glucose, maltose, can also partially dis-
place cytochalasin B from glucose carrier. By contrast, other
hexose like fructose disaccharides like sucrose and lactose
pentose like arabinose amino sugar like glucosamine cannot
displace cytochalasin B from glucose carrier. Furthermore,
this glucose carrier is stereospecific for D-glucose since L-
glucose cannot displace cytochalasin B from this carrier
molecule. L-fucose cannot displace cytochalasin B from glucose
carrier too.
VI. Effect of serum glucose on the number of glucose carrier it
Ehrlich ascites tumor cells in vivo
The changes in serum glucose and the glucose level of
ascites fluid during tumor development are shown in Fig. 22.
In examining the serum glucose of tumor bearing mice, it was
found that hypoglycemia appeared during the development of
tumor. This result agrees with the findings of other tumor
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Fig. 22 Concentration of glucose in mouse serum and ascites fluid
during tumor development. Mice were inoculated with 107
tumor cells on day 0. Glucose levels in serum (p-®) and
ascites fluid (0- 0) were determined on indicated days post
transplantation. Values are expressed as the mean± S.E.M.
for three separate experiments. Blood samples were obtained
from mice after overnight fasting. Values of day 0 represent
the relative glucose levels of normal mice. The glucose level
in peritoneal fluid of normal mice was obtained from the
result of Nakamura and Hosada (1968). The broken line is the
estimation of the change in glucose level in peritoneal




cell lines (Vaissman et aZ 1964 Goranson et al 1954 Goranson
and Tilser 1955 Tagi-Zade and Shapot 1971). The serum glucose
fell from 115 mg/100 ml on day 0 to 44 mg/100 ml on day 11 post
transplantation. By contrast, there was essentially no measur-
able glucose in the ascites fluid from day 2 to day 11 after
the tumor inoculation and this result is consistent with the
finding of Nakamura and Hosoda (1968). It should be noted that
during the development of tumors, serum glucose of the hosts
decreased progressively but by contrast the number of glucose
carrier in the tumor cells increased progressively( Fig 6 and
Fig 22). The relationship between serum glucose of the host
and the number of glucose carrier of the tumor cells can be
observed in the plot of serum glucose versus the reciprocal of
carrier number (Fig. 23). A best-fit linear plot was obtained
by linear regression with the correlation coefficient greater
than 0.918. Therefore we can conclude that the carrier number
on tumor cells are closely related to serum glucose of the host
and the change in the number of glucose carrier on the tumor
cells may be caused by the decrease in serum glucose of the
host.
It has been demonstrated that the number of glucose carrier
on cultured chick embryo fibroblasts is closely regulated by the
level of glucose in culture medium. It was suggested that
glucose acts as a repressor for carrier synthesis (Amos,
Musliner and Asdourian 1977). Therefore whether serum glucose
has any effect on the number of glucose carrier on Ehrlich
as cites tumor cells in vivo was studied.
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Fig. 23 The relationship between serum glucose of the host and the
number of glucose carriers (Bo) in the tumor cells during
tumor development. The reciprocal of Bo values of different
days post transplantation are plotted versus the serum
glucose of the mice on the corresponding days. The line
was the best fit according to linear least squares analysis
and with correlation coefficient greater than 0.918. Values





Insulin and streptozotocin were injected into different
groups of mice to produce hypoglycemia and hyperglycemia res-
pectively. The mice were then inoculated with Ehrlich ascites
tumor cells. The serum glucose levels of the mice were examined
.during tumor development. As shown in Fig. 24, serum glucose
of insulin-treated mice was lower than that of untreated mice
while the serum glucose levels of streptozotocin-induced dia-
betic mice were much higher than that of untreated mice.
Injection of insulin to the streptozotocin-induced diabetic
mice can abolish the hyperglycemia and restore the serum glucose
level of streptozotocin-treated mice to normal range.
On day 7 post implantation, all groups of mice were killed
and their tumor cells were harvested by exhaustive drainage.
The tumor cell number was determined with haemocytometric cell
counting. Table 3 shows the tumor size of the four different
groups, the tumor size of control group is the largest.
Insulin treatment has little effect on tumor growth while the
injection of streptozotocin can cause a drastic and statis-
tically significant reduction (p 0.01) by about 80% in the
tumor size. Injection of insulin to the streptozotocin-induced
diabetic mice can only partially restore the tumor size of the
mice.
Table 4 shows the number (Bo) and the dissociation constant
(Kd) of glucose carriers on Ehrlich ascites tumor cells har-
vested from different groups of mice bearing 7 day-old tumors.
88
Fig. 24 Concentration of glucose in mouse serum during tumor
development. Serum glucose of(O- 0) untreated mice,
(*-') insulin induced hypoglycemia mice, (0-0) strepto-
zotocin-induced diabetic mice and (-) streptozotocin-
induced diabetic mice with insulin treatment were determined
every 2 days after tumor inoculation. indicates day
of injection of streptozotocin (200 mg/kg body weight).
indicates the days of injection of insulin( a- 4 IU/mouse,
b- 3 IU/mouse, c- 2 IU/mouse and d- 1 IU/mouse).
indicates the day of inoculation of tumor cells. Broken
lines are the estimation of changes in serum glucose of
different groups relative to untreated group. Values are
presented as the mean± S.E.M. for two separate experiments.
FIGURE 24
DAYS
TABLE 3. EFFECT OF STREPTOZOTOCIN AND INSULIN TREATMENT ON THE TUMOR SIZE OF EHRLICH
ASCITES TUMOR BEARING MICEa
Groups Treatment Tumor size of 7 day- Percentage of reduction
old tumors
(10® cellmouse)
I Nil 11.5± 0.4 0
II Insulin injection every36 hours 9.2± 0.5 20% (p 0.1)
TTT Streptozotocin-induced diabetes 6.6± 0.6 43% (p 0.05)
with insulin treatment
IV Streptozotocin-induced diabetes 2.2± 0.5 81% (p o.or
a. The treatment of streptozotocin and insulin to the tumor bearing mice was performed as
described in the text. The values are presented as mean± S.E.M. for 2 separate experiments.
TABLE 4. IN VIVOEFFECT OF STREPTOZOTOCIN AND INSULIN TREATMENT ON THE APPARENT
DISSOCIATION CONSTANT (Kd) AND THE NUMBER (Bo) OF GLUCOSE CARRIER ONt
EHRLICH ASCITES TUMOR CELLS3
Groups Treatment Bo (pmol10 cell) (10 M)% change in Bo
I Nil 211.7± 5.0 2.52± 0.08 0
II Insulin injection every 36 hours 259.7± 6.2 2.76± 0.06 + 23
III Streptozotocin-induced diabetes 177.4± 4.6 2.28± 0.06 - 16
with insulin treatment
IV Streptozotocin-induced diabetes 117.3± 3.5 2.60± 0.0
A
- 45
a. Treatment of streptozotocin and insulin to the tumor bearing mice was performed as described in
the text. The values are presented as mean± S.E.M. for triplicate determinations of 2 separate
experiments.
p value for the significance of difference 0.001.
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Bo in Ehrlich ascites tumor cells harvested from untreated
mice is 212 pmol/107 cell. Ehrlich ascites tumor cells
harvested from the insulin-induced hypoglycemic mice showed
Bo of 260 pmol/107 cell. The difference between these two
values is statistically significant (p 0.001). By contrast
Bo of tumor cells harvested from the streptozotocin-induced
diabetic mice significantly decreases to 117 pmol/107 cell
with p 0,001 as compared with the value in those cells
harvested from untreated mice. Injection of insulin to this
diabetic group can partially restore the serum glucose to
normal range as well as the Bo to 177 pmol/107 cell in the
tumor cells.
The relationship between serum glucose of the tumor
bearing mice and the number of glucose carriers (Bo) in the
tumor cell can be further confirmed in Fig. 25. In the
figure, the reciprocal of Bo for 7 day-old tumors harvested
from the four different groups of mice was plotted versus
the serum glucose on day 7 post tumor transplantation of
the corresponding group of mice. A best-fit straight line
was obtained by linear regression method with correlation
coefficient about 0.990. It is more conclusive that the
glucose carriers number (Bo) on tumor cells are closely
related to serum glucose of the hosts and the change in Bo
on the tumor cells may be caused by the changes in serum
glucose of the host.
The Kd of the glucose carrier on the tumor cells remained
93
Fig. 25 The relationship between serum glucose of the hosts treated
with insulin or streptozotocin and the number of glucose
carrier (Bo) in Ehrlich ascites tumor cells harvested from
the treated and untreated mice. The reciprocal of Bo values
for different groups (Table 4) are plotted versus the serum
glucose of mice bearing 7 day-old tumors (Fig. 24) of the
corresponding groups. The line is the best fit according to
linear least squares analysis and with correlation coefficient
about 0.990. Values are expressed as the mean and determined
from Fig. 24 and Table 4.
a. insulin-treated group
b. untreated mice
c. streptozotocin-induced diabetes with insulin treatment and
d. streptozotocin-induced diabetic mice.
FIGURE 25
SERUM GLUCOSE mg/100,l)
unchanged in both four groups indicating that the nature of
the glucose carriers may not be affected by streptozotocin
or insulin. Base on the above results, it can be interpreted
that the number of glucose carrier (Bo) in tumor cells is
. closely related to the serum glucose levels of their hosts.
However, the direct effect of insulin on Bo may not be ruled
out since injection of insulin to the mice caused an increase
in Bo, tumor cells harvested from mice with depletion of
insulin by streptozotocin caused a decrease in Bo and
injection of insulin to streptozotocin-induced diabetic
(insulin deficient) mice can partially restore their Bo
value. Furthermore, it has been shown that insulin can
increase glucose carriers on plasma membrane pool and
stimulate the translocation of glucose carriers from micro¬
somal pool to plasma membrane in adipocytes (Karnieli et al
1981; Sogin and Hinkle 1980; Suzuki and Kono 1980). To
differentiate whether Bo on Ehrlich ascites tumor cells is
affected by glucose or insulin, direct effect of insulin on
Bo was examined.
VII. Effect of hormones on the number of glucose carrier (Bo) in
Ehrlich ascites tumor cells
Table 5 shows the number (Bo) and apparent dissociation
constant (K) of glucose carriers on Ehrlich ascites tumor
cells after incubation with different hormones. The incuba¬
tion of Ehrlich ascites tumor cells in incubation buffer at
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37°C for 60 minutes (group II) has no effect on Bo and Kd
comparing with group I (p>0.1). The addition of insulin
at a low concentration (group III, 2 ug/ml, i.e. 0.05 unit/ml)
or a high concentration (group IV, 20 ug/ml, i.e. 0.5 unit/ml)
in the incubation buffer and incubating for 60 minutes does
not affect Bo. However, addition of glucagon (group V, 5 x
10-3 mg/ml) caused a significant reduction comparing with
group II (p< 0.001) in Bo by about 35%. Similarly, the
addition of corticosterone (group VI, 25 x 10-3 mg/ml) and
its metabolite, cortisone (group VII, 25 x 10-3 mg/ml), also
caused significant reduction comparing with group II
(p 0.001) in Bo by about 34% and 36% respectively. The
Kd values of the glucose carriers on Ehrlich ascites tumor
cells are not affected by the addition of various hormones
throughout incubation.
According to the results shown above, the direct effect
of insulin on Bo in Ehrlich asc,ites tumor cells may be
insignificant. In order to further investigate the effect
of extracellular glucose level on Bo, the tumor cells were
incubated with different glucose concentration in medium
in vitro to see whether there is any change in Bo after the
incubation.
TABLE 5. THE EFFECT OF DIFFERENT HORMONES ON THE APPARENT DISSOCIATION CONSTANT (Kd) AND THE NUMBER (Bo) OF
%
GLUCOSE CARRIER ON EHRLICH ASCITES TUMOR CELLS AFTER IN VITRO INCUBATION3
Groups Hormones added Concentration of
the hormones









































a. The incubation of various hormones with 7 day-old tumor cells was performed as described in the text.
me values are presented as mean± S.E.M. for triplicate sample determinations of 2 separate experiments.
b. Without incubation at 37° C
c Not comnared
d- With incubation at 37° C for 60 minutes
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VIII. The effect of glucose in incubation medium on the number of
glucose carriers in Ehrlich ascites tumor cells in vitro
Ehrlich ascites tumor cells were incubated in RPMI 1640
medium supplemented with glucose either at 5.5 mg/ml or 1.9
--mg/ml. Aliquots of tumor cell suspension were taken out at
different time intervals. The supernatants of cell suspension
were tested for glucose concentration and the tumor cells were
harvested and washed twice with PBS, and the washed cells were
then tested for glucose carrier content. Fig. 26 shows the
changes in glucose concentration in the medium and the Bo in the
tumor cells throughout the incubation in low glucose medium (1.9
mg/ml). Curve A shows the glucose concentration in the medium
at different time points. The glucose concentration fell from
1.88 mg/ml at time zero to zero concentration at 8 hours post
incubation and remained at the value of zero concentration
afterwards. Curve B shows the changes in Bo throughout the in-
cubation. Bo decreased by about 12% in the first 2 hours of in-
cubation. In the period of 2 hours to 8 hours post incubation,
Bo increased to the original value and remained unchanged until
14 hours post incubation. However in the period of 14 hours to
26 hours post incubation, Bo increased drastically. The values
of Bo at 20 hours and 26 hours post incubation were 276 and 302
pmol/107 cell respectively. These increments were about 28%
(p 0.005) and 40% (p 0.005) respectively comparing with the
Bo of 215 pmol/107 cell at time zero. Fig. 27 shows the changes
in glucose concentration in the medium and Bo in tumor cells
throughout the incubation in high glucose medium (5.5 mg/ml).
99
Fig. 26 The effect of glucose concentration of the medium on the
number of glucose carriers (Bo) in Ehrlich ascites tumor
cells incubated in the medium. Curve A shows the change
in glucose concentration(-) in the low glucose medium
(1.9 mg/ml). Curve B (O-O) shows the change in Bo in the
tumor cells. Bo value increase by about 28% (p 0.005) and
40%( p<0.005) for 20 and 26 hours post incubation
respectively comparing with the value of the beginning of





Fig. 27 The effect of glucose concentration of the medium on the
number of glucose carriers (Bo) in Ehrlich ascites tumor
cells incubated in the medium. Curve A shows the change in
glucose concentration(*-*) in the high glucose medium
(5.5 mg/ml). Curve B(0-0) shows the changes in Bo in the
tumor cells. Bo values decrease by about 32% (p 0.001) in
the first 8 hours of incubation comparing with the value of
the beginning of incubation. Values are presented as the
mean± S.E.M. for triplicate determintations.
FIGURE 27
HOURS
TABLE 6. THE APPARENT DISSOCIATION CONSTANT (Kd) OF GLUCOSE CARRIER ON EHRLICH ASCITES TUMOR CELLS AFTER
INCUBATION IN RPMI 1640 MEDIUM IN VITROa:
Time of incubation (hours) Apparent dissociation constant (K) (10 M)



















a. The tumor cells were incubated in low glucose (1.9 mgml) and high glucose (5.5 mgml) medium. The
incubation was performed as described in the text. The value for these two groups are apparently
remained unchanged. The p values for the significance of difference for low glucose medium group is
0.05 and that for high glucose medium group is 0.1. Values are presented as mean± S.E.M. for
triplicate determinations.
Curve A shows the glucose concentration in the medium at dif¬
ferent time points. The glucose concentration fell progressive¬
ly from 5.53 mgml at the beginning to 2.53 mgml at 26 hours
post incubation. Curve B shows the changes in Bo throughout
incubation. Bo decreased by about 32% in the first 8 hours and
afterwards it began to rise gradually and reached the original
value at about 22 hours post incubation. Then it remained
relatively unchanged until 26 hours post incubation. Table 6
shows the values of apparent dissociation constant (K) of the
glucose carriers on Ehrlich ascites tumor cells at different
time points. There are no significant change in K for highd
glucose group (p 0.1) and low glucose group (p 0.05)
throughout the incubation period, furthermore, K value is alsod
not affected by the glucose concentration of the medium in which
the tumor cells were incubated.
IX. In vivo effect of methotrexate (MTX) on 2-deoxy-D-glucose uptake
and the clucose carrier on Ehrlich ascites tumor cells
The effect of methotrexate (MTX) on the uptake of 2-deoxy-
D-glucose and glucose carrier on Ehrlich ascites tumor cells
was studied with 7 day-old tumor cells. Administration of 0.4
mg MTX per Kg body weight can decrease the tumor size of tumor
bearing mice (Table 7). Earlier administration of MTX (on days
2, 4 and 6) caused a greater reduction (by about 53%) in tumor
size than that (by about 31%) caused by later administration
( on days 4, 5 and 6). Administration of MTX on days 4, 5 and
6 post transplantation reduced the Vmax of the uptake process
significantly (p <0.005) by about 25% (Table 8). This decrease
could be shown to be due principally if not exclusively to a
reduction in Bo per cell, as evidenced by the 25% reduction in
the Bo value in MTX-treated cells when compared with that of
untreated cells (Table 9). The apparent value for the hexose
uptake process was unaffected by MTX; correspondingly, no sig-
nificant difference was obtained for the apparent dissociation
constant (K) for the glucose carriers (p 0.1) (Table 8 and
Table 9). Table 8 also shows that MTX administratered on days
2, 4 and 6 post transplantation, which was more effective in
reducing tumor size, brought about a more pronounced drop in the
rate of glucose uptake, and a bigger reduction in the Bo (Table
9). The magnitude of changes in the later two parameters was
again comparable, 35% versus 40%. Similarly, the values of IT M
and K were not affected by the administration of MTX (p> 0.1)
(Table 8 and Table 9). Furthermore, the values of I and
were not affected by the time intervals of MTX administration.
TABLE 7. THE EFFECT OF METHOTREXATE (MTX) ON THE TUMOR SIZE OF THE TUMOR BEARING MICE IN [J[0a
Groups Dosage of MTX Days of MTX administra- Turaor size % reduction
(mgKg body wtinjection) tion post implantation (108 cellmouse)
Control 0 0 10.8± 0.4 0
A 0.4 2, 4, 6 5.1± 0.2 53
(p 0.01)
B 0.4 4,5,6 7.4± 0.3 31
(p 0.05)
a. The values represent the tumor size of mice on day 7 post tumor transplantation and are expressed
as mean± S.E.M. for 3 separate experiments.
TABLE 8. THE EFFECT OF METHOTREXATE (MTX) ON MAXIMAL UPTAKE RATE (Vmax) AND APPARENT HALF-SATURATION
CONSTANT (Km) OF THE PROCESS OF 2-DEOXY-D-GLUCOSE UPTAKE BY EHRLICH ASCITES TUMOR CELLSa
Groups 2-deoxy-D-glucose uptake % redcution in Vmax













a. The uptake of 2-deoxy-D-glucose was measured as described in the text using the cells harvested from
treated and untreated 7 day-old tumors. Values are expressed as mean 1 S.E.M. of triplicate
sample determinations.
b. Mice were administered with 0.4 mgKg body wt MTX on days 2, 4, 6 post tumor inoculation.
c. Mice were administered with 0.4 mgKg body wt MTX on days 4, 5, 6 post tumor inoculation.
TABLE 9. THE EFFECT OF METHOTREXATE (MTX) ON APPARENT DISSOCIATION CONSTANT (K) AND THE NUMBER (Bo) OF GLUCOSE
CARRIERS IN EHRLICH ASCITES TUMOR CELLSa
Groups Glucose carrier % reduction in Bo
Bo (pmol10 cell) Kd (10~7 M)
Control 221.3± 7.9 2.48± 0.07 0
Ab 130.0± 9.8 2.20± 0.08 41 (p 0.001)
Bc 162.8± 7.2 2.17± 0.11 26 (p 0.001)
a The glucose carriers were measured as described in the text using cells harvested from treated or un¬
treated 7 day-old tumors. Bo and were obtained from Scatchard analysis of the difference in binding
in the absence and in the presence of 500 mM of D-glucose. Values are expressed as mean± S.E.M. of
triplicate sample determinations from 2 separate experiments.
b. ilice were administered with 0.4 mgKg body wt MTX on days 2, 4, 6 post tumor inoculation.
c. Mice were administered with 0.4 mgKg body wt MTX on days 4, 5, 6 post tumor inoculation.
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DISCUSSION
Changes in glucose uptake by Ehrlich ascites tumor cells duringI.
tumor development in vivo
The present study showed that the rate of glucose uptake by
Ehrlich asciter tumor cells increased progressively as the tumor
developed (Fig. 4). When present at high enough concentration,
glucose can enter cells at .a significant rate by simple diffusion
(unsaturable diffusion) (Fig. 3B Renner, Plagemann and
Bernlohr 1972 Plagemann and Richey 1974). The negligibly
low level of glucose in the ascites fluid (Fig. 22), however,
would require that, in vivo, Ehrlich ascites tumor cells
obtained glucose through a facilitated transport process and
this is consistent with the idea of Fishman and Bailey (1974).
Such a process has been shown to follow simple Michaelis-
Menten kinetics and may adequately be described by the kinetic
parameters, Vmax and KM (Plagemann and Richey 1974 Kaminskas
1979). The data presented in Fig. 4 showed that the Vmax for
glucose uptake increased continuously with tumor growth but
the KM value remained constant throughout.
Methotrexate, an antimetabolite demonstrated to inhibit
glucose consumption by cultured Ehrlich ascites tumor cells
(Kaminskas and Nussey 1978) was also seen in the present study
to decrease glucose uptake by lowering the Vmax value without
appreciably affecting the K11 value (Table 8, group A and B).
Increased glucose and nucleosides uptake has been accompany
phytohaemagglutinin-stimulated proliferation of cultured
bovine lymphocytes (Peters and Hausen 1971 a and b) as well as
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the virus-induced neoplastic transformation of several avian
and mammalian cell lines (see Hatanaka 1974 for review)
including Rous sarcoma virus/chick embryo fibroblasts (Martin
et aZ 1971 Hatanaka and Hanafusa 1970 Lee and Lipmann 1977
Lawrence and Jullien 1980), polyoma virus/mouse BHK cells
(Isselbacher 1972) and hamster pseudotype sarcoma virus/hamter
embryo cells (Hatanaka, Gilden and Kelloff 1971). Normal cell
lines including mouse and chick cells in culture, on the other
hand, exhibited reduced transport rates when they attained
confluency (Bose and Zlotnick 1973 Rubin 1972), as did rat
3T3-L1 fibroblasts upon conversion to adipocytes with dexameth-
asone/1-methyl-3-isobutylxanthine treatment (Resh 1982). The
changed glucose transport rate in each case was shown to be the
result of changes in values of Vmax rather than KM. In this
respect, glucose transport in these experimental system resem-
bles that in Ehrlich ascites tumor cells. Transport rates
changed because of changes in the number and/or operational
efficiency of transport sites the affinity between glucose
and its transport component was not affected, at least not in
the aforementioned circumstances.
II. Characteristics of glucose-sensitive cytochalasin B binding
sites on Ehrlich ascites tumor cells
In nearly all eukaryotic cells studied, glucose transport
occurs as a carrier-mediated process (see Jones and Nickson
1981 for review). Cytochalasin B inhibits this process and a
set of high-affinity glucose inhibitable binding sites for
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cytochalasin B has been tentatively identified to be the
glucose transporter (Karnieli et aZ 1981 Cuppoletti, Mayhew
and Jung 1981 Sogin and Jung 1981 Sogin and Hinkle 1980a
Suzuki and Kono 1980 Jung and Rampal 1977). Studies performed
on this glucose-reversible cytochalasin B binding activity in
cell systems as divergent as human erythrocytes, Novikoff rat
hepatoma cells and barnacle muscle cells (Cuppoletti, Mayhew
Jung 1981 Renner,Plagemann and Bernlohr 1972 Sogin and Hinkle
1980a Jung and Rampal 1977 Baker and Carrnthers 1980) reveal-
ed that they share a number of common characteristics: (1) a
high affinity for cytochalasin B (Kd 1-6 x 10-7 M) (2) stereo-
specific inhibition by sugar thus D-glucose, 3-0-methyl-D-
glucose, 2-deoxy-D-gluocse, D-galactose and D-mannose inhibit
binding L-glucose and L-fucose are without effect and (3)
sensitivity to phloretin and diethylstilbestrol.
These properties are also examined in the present studies
with Ehrlich ascites tumor cells (Fig. 5A and 5B, Fig. 8A and
8B, Fig. 9A and 9B, Fig. 10A and 10B, Fig. 11A and 11B, Fig.
13A and 13B, Fig. 14A and 14B, Fig. 15, Fig. 17 and Table 2).
It is found that the dimer of glucose, maltose, can also
partially displace cytochalasin B from its binding sites.
However, other disaccharides like lactose, dimer of galactose
and glucose, and sucrose, dimer of fructose and glucose, cannot
displace any cytochalasin B from its binding sites. It seems
that the existence of other saccharides in the glucose-
containing disaccharides will hinder the binding of these di-
saccharides to the glucose-sensitive cytochalasin B binding
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sites. On the other hand, monosaccharides like 3-0-methyl-D-
glucose and 2-deoxy-D-glucose, which are derivatives of D-
glucose, can completedly displace while D-mannose and D-
galactose can only partially displace cytochalasin B from its
binding sites. By contrast, fructose,arabinose cannot undergo
this displacemant. The binding sites seem to be stereospecific
that no binding can be observed in L-glucose. Clucosamine,
with an amine group on glucose molecule, cannot bind to the
glucose-sensitive cytochalasin B binding sites on Ehrlich
ascites tumor cells. This observation is in contrast with
that reported in other cell lines (Plagemann et aZ 1981
Hatanaka 1974).
Recently, Griffin, Rampal and Jung (1982) suggested that
cytochalasin B bound to the glucose carrier on human erythro-
cytes through hydrogen bond at N2 (donor), 07 (acceptor), and
023 (acceptor) analogous to 06, 03 and 01 respectively on 13-
D-glucose. The hydrophobic region from C13 to C19 also essen-
tial in binding to carrier molecules and appears to act as
an anchor in a hydrophobic domains of the glucose carrier.
The structures of cytochalasin B and various sugars are shown
below and the indicated area(*) is the group suggested to be
responsible for the binding.









Structures of the sugars which can bind on glucose-





Structures of the sugars which cannot bind on glucose-





According to the proposal of Griffin, Rampal and Jung
(1982), all monosaccharides and disaccharides bearing the same
configuration of 06, 03 and 01 as in (3-D-glucose like 3~D-
mannose, 3-D-galactose, 2-deoxy-3~D-glucose, 3-0-methyl-3-D-
glucose, 3-D-glucosamine, maltose and lactose can bind on glucose-
sensitive cytochalasin B binding sites and displace cytochala-
sin B from these sites. While other sugars with different
configuration of 06, 03 and 01 as 3-D-glucose like D-fructose,
D-arabinose, L-fucose, L-glucose and sucrose cannot bind on
these glucose-sensitive cytochalasin B binding sites.
This postulation can only be confirmed in parts in our
experiments. D~fructose, D-arabinose, L-fucose, L-glucose
and sucrose cannot bind on glucose-sensitive cytochalasin B
binding sites on Ehrlich ascites tumor cells as expected.
However, the present study showed that D-mannose and D-
galactose can only partially displace cytochalasin B from its
glucose-sensitive binding sites and even no displacement
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could be observed in lactose and glucosamine. The glucose
uptake inhibitors, plioretin and diethylstilbestrol can also
displace cytochalasin B from its glucose-sensitive binding
sites, our results showed that they might bind to the glucose-
sensitive cytochalasin B binding sites on Ehrlich ascites
tumor cells and compete with cytichalasin B. However, Jennings
and Solomon (1976) suggested that these uptake inhibitors
may affect the dipole potential at membrane surface. The
nature of substrate specificity of the glucose-sensitive
cytichalasin B binding sites on Ehrlich ascites tumor cells
and other cell lines remains not known and awaits further
investigations.
Ill. Identification of glucose-sensitive cytichalasin B binding
sites as glucose carriers on Ehrlich ascites tumor cells
There are three experimental evidences which strongly
suggest that the glucose-sensitive cytochalasin B binding
sites are identical to the glucose carriers on Ehrlich ascites
tumor cells. Firstly, it should be noted that in nearly all
eukaryotic cells studied, glucose-sensitive cytochalasin B
binding sites on the cells are believed to be identical to the
glucose carriers on these cells (see Jones and Nickson 1981
for review). Both the three common characteristics of the
glucose carriers in all other cell lines studied, namely, high
affinity for cytochalasin B binding, stereospecificity for D-
form of sugars and sensitivity to glucose uptake inhibitors,
has been shown to be shared by the glucose-sensitive cytochala-
sin B binding sites on Ehrlich ascites tumor cells. The struc¬
ture of these sites on Ehrlich ascites tumor cells may be very
close to those of other cells or they may even share a certain
degree of common structure with those on other cell lines.
Secondly, the increase in number of putative glucose-
sensitive cytochalasin B binding sites sufficiently accounted
for the elevated rate of glucose uptake associated with tumor
development. Fig. 4 shows that between day 2 and day 9 post
transplantation, the Vmax value for glucose uptake process
increased approximately 3.3 fold. During the same period,
the maximal number of glucose-sensitive cytochalasin B bind¬
ing sites increased 3.4 fold (Fig. 6). Furthermore, the
increase in glucose uptake rate progressively during tumor
development was well correlated with the increase in glucose-
sensitive cytochalasin B binding sites on Ehrlich ascites
tumor cells during the same period (Fig. 7).
Thirdly, it may be seen that methotrexate suppressed the
uptake of 2-deoxy-D-glucose in 7 day-old tumor cells to the
same extent as glucose-sensitive cytochalasin B binding was
inhibited (Table 8 and Table 9). Furthermore, the fact that
methotrexate was without effect on the for the cytochalasin
B binding (Table 9) corroborates our earlier assertion that
qualitative changes in the transport process are not related to
substrate binding. It may therefore be concluded that changes
in glucose uptake by Ehrlich ascites tumor cells are principally
the result of changes in the number of transport carriers.
While alteration in the turnover rate of glucose carriers can-
not be absolutely ruled out in the present study, its contri¬
bution to the overall transport process is at best minimal.
A similar conclusion has been reached by Wardzala et al (1978)
for the effect of insulin on glucose transport in rat adipocytes.
If the postulation that this class of cytochalasin B bind¬
ing sites are identical to the glucose carrier is valid, the
data presented in Fig. 6 may be interpreted to mean that as the
Ehrlich ascites tumor cells grew, the number of glucose carrier
increased and thus glucose uptake increased.
The high density of glucose carriers on Ehrlich ascites
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tumor cells is remarkable and unique among other animal cells
in its high content of this site. In 7 day-old cells, the
maximal binding of 220 pmol/107 cell (Table 9) translates to
1.3 x 107 carrier molecules/cell. This is in close agreemant
with the value estimated by Cuppoletti et aZ (Cuppoletti et
aZ 1981) in cultured Ehrlich ascites tumor cells and is con-
siderably higher (3-100 fold) than that reported for human
erythrocytes, Hela cells and Novikoff rat hepatoma cells
(Sogin and Hinkle 1980a Lin, Santi and Spudich 1974 Plage-
mann, Graff and Wohllueter 1977). This observation may pro-
bably reflects the fact that the other cells are mainly
dependent on respiration for the provision of metabolic energy
(Freudenberg and Mager 1971 Plagemann and Erbe 1973 Schwartz
and Johnson 1976), Ehrlich ascites tumor cells depend primarily
on glycolysis and a high-capacity system for glucose uptake is
essential for the maintenance of growth (Kaminskas and Nussey
1978). The continuous fall in serum glucose during tumor
development (Fig. 22) is a reflection of this high demand for
glucose and the efficiency of the glucose carrier on Ehrlich
ascites tumor cells.
IV. Change in the number of glucose carriers in Ehrlich ascites
tumor cells during tumor development
The increases in glucose uptake and the number of glucose
carriers during tumor development is difficult to explain.
When 7 day-old tumor cells possessing about 200 pmol/107 cell
were inoculated into normal mice, a 4-fold decrement in the
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number of glucose carriers was observed within 48 hours post
transplantation (Fig. 6). The glucose concentration in normal
mice peritonael fluid is 95 mg/100 ml (Nakamura and Hosoda
1968). Once the tumor cells were inoculated, glucose concen-
tration in ascites fluid decreased to apparently zero within
48 hours post transplantation (Fig. 22). From this time on,
tumor cells were under glucose starvation. There are a large
body of evidences showing that glucose starvation results in
an apparent enhancement of glucose uptake in chick embryo
fibroblasts, hamster rodent cells, human HSWP cells and Hela
cells in vitro (Martineau et aZ 1972 Kalcker and Ullrey 1973
Hatanaka 1973 Shaw and Amos 1973 Kletzien and Perdue 1975
Salter and Cook 1976 Christopher, Colby and Ulirey 1976
Muskiner, Chrousos and Amos 1977 Salter and Cook 1975 Venuta
and rubin 1975). This transport enhancement is RNA transcrip-
tion and protein synthesis dependent. Banjo and Perdue (1976)
and Adams et aZ (1977) both could identify two membrane
proteins whose rate of synthesis was accelerated when chick
cells were starved of glucose and protein synthesis was also
observed in Rous sarcoma virus-transformed chick cells (Weber
1973 Hatanaka 1974 Lee and Lipmann 1977 Lawrence and Julien
1980). The implication for the increase in glucose uptake
during glucose starvation is that glucose transporters are
involved. Moreover, restoration of glucose to the medium on
starved cells leads to a reversal of the glucose uptake enhan-
cement to control value. It seems reasonable to postulate that
glucose carriers on the cells are regulated by the
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extracellular. glucose concentration. Low glucose concentra-
tion can trigger the synthesis of glucose carriers while high
glucose concentration can suppress the synthesis of carrier
molecules. Christopher and coworkers (Christopher et al 1976
Christopher, Colby and Ullrey 1976) proposed that regulation
in glucose transport carrier involves the turnover of compon-
ents of glucose uptake systems on the one hand and glucose
carrier synthesis which may or may not be alternatively
accelerated and restrained on the other. Amos et al (1977)
showed that hexose deprivation stimulates glucose uptake 30-
fold in chick embryo fibroblasts. They showed that external
energy source provided by a non-repressor sugar (D-fructose,
D-xylose) or by pyruvate is required to accomplish carreir
synthesis in glucose starved state. Furthermore glucose acts
as a repressor at a posttranscriptional step probable at the
level of turnover of formed carrier. Since the potection of
formed carrier in the absence of glucose and by inhibitors of
protein synthesis even in the presence of glucose has encour-
aged conjecture that a protease is activated by a metabolic
product of glucose that is analogous to a corepressor. The
metabolite either activates the protease by direct interaction
with it or alters the conformation of the carrier molecules
to expose a critical region to protease attack. The regulation
of carrier density in the membrane may be archieved entirely
by carrier inactivation, the rate of which is a function of
glucose concentration in the culture medium. If these repres-
sion and derepression hypothesis for glucose uptake attributed
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by glucose carrier molecules also appeared in Ehrlich ascites
tumor cells, the number of glucose carriers in Ehrlich ascites
tumor cells changes during tumor development in vivo may also
be due to the high glucose concentration in normal mice per-
itoneal fluid which causes repression in glucose carrier, and
the absence of glucose in ascites fluid resulting derepression
in glucose carrier.
V. Relationship between glucose concentration and glucose carriers
on Ehrlich ascites tumor cells
The glucose presented in peritoneal fluid was deliveried
from the systemic circulation. In normal mice, glucose con-
centration in peritoneal fluid is 95 mg/100 ml. When 7 day-
old Ehrlich ascites tumor cells were exposed to this high
concentration of glucose, their glucose carrier density might
be under the regulation of repression and decreased by about 4-
fold and glucose could enter the tumor cells by simple diffu-
sion (unsaturable diffusion). Therefore decrease in the number
of glucose carrier in Ehrlich ascites tumor cells when exposed
to fresh peritoneal fluid within 48 hours post transplantation
could be explained by external glucose regulation. However,
Ehrlich ascites tumor cells metabolized glucose at a extremely
high rate, as they proliferated in the peritoneal cavities of
of the mice, glucose in ascites fluid was used up. Because of
the glucose concentration gradient between systemic circulation
and ascites fluid, serum glucose would be continuously deli-
veried into the peritoneal cavities of the Ehrlich ascites
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tumor bearing mice, but once the glucose was flowed in, it was
metabolized by the tumor cells. Therefore in ascites fluid,
glucose concentration was essentially undetectably low. The
serum glucose decreased progressively during tumor development,
the delivery rate of serum glucose to ascites fluid would also
decreased progressively within the same period since the decrease
in glucose concentration gradient. However, tumor cells could
proliferate and increase their cell number during tumor develop-
ment. Therefore it is reasonable to suggest that under glucose
starvation, Ehrlich ascites tumor cells should not only possess
an active transport system with a high affinity for glucose but
also possess the ability to increase its glucose carrier to take
up glucose required for their proliferation during development.
This may represent a useful adaptive capability of tumor cells.
The apparent low KM value (about 0.6 mM) of glucose uptake process
in Ehrlich ascites tumor cells can take up glucose from ascites
fluid in which glucose concentration is undetectably low (Fig.
22). Fig. 23 can clearly show that the number of glucose carriers
in Ehrlich ascites tumor cells is well correlated with the level
of serum glucose of the hosts.
In order to investigate the above postulation, insulin and
streptozotocin were injected to produce hypoglycemia and hyper-
glycemia in tumor bearing mice. Streptozotocin can destroy pan-
creatic (3-cells and deplete insulin in mice in vivo. As expected,
Ehrlich ascites tumor cells harvested from insulin-treated hypo-
glycemic mice showed an increase in glucose carrier content com-
paring with control group while Ehrlich ascites tumor cells harvested
from streptozotocin-treated hyperglycemic mice showed a reduction
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in glucose carrier content comparing with untreated mice. The
differences are statistically significant. In addition, injec-
tion of insulin to streptozotocin-induced diabetic mice resulting
in reversal of hyperglycemia showed a restoration of glucose
carrier on Ehrlich ascites tumor cells harvested from this group
(Table 4). Again, a good correlation between serum glucose with
the number of glucose carriers on different groups of tumor cells
can be seen (Fig. 25). However, the results of this experiment
cannot conclusively prove the direct effect of serum glucose on
glucose carrier density in Ehrlich ascites tumor cells. Many
workers (Suzuki and Kono 1980 Carter-Su et al 1981 Karnieli
et al 1981 Kono et al 1981 Resh 1982) showed that insulin can
increase the. glucose uptake as well as glucose carrier in adipo-
cytes due to translocation of glucose carrier from microsomal
fraction to plasma membrane. Therefore the results of the
present study on Ehrlich ascites tumor cells can be alternatively
interpreted that the changes in glucose carrier on Ehrlich ascite
tumor cells harvested from different groups of mice are caused by
the excess or deficiency of insulin.
In order to differentiate these two possibilities, the
direct effect of insulin on glucose carrier density in Ehrlich
ascites tumor cells was studied. During tumor development,
hypoglycemia caused by the development of tumor cells might
stimulate the secretion of glucagon and glucocorticoid. In
addition, it has been reported that steroid hormones like gluco-
corticoid, corticosterone and its metabolite, cortisone can
decrease the glucose transport by human erythrocytes (Lacko,
Wittke and Geck 1975) at a competitive manner. However the
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mode of action of steroids on biological membrane at the
molecular level, for examples their effects on the glucose
carrier density and glucose uptake rate of tumor cells are
still obscure. Therefore it is of interest to find out whether
glucagon and glucocorticoid increase or decrease the glucose
carrier of the tumor cells. Since the injection of these hor-
mones to tumor bearing mice may complicate the serum glucose
concentration, the effect of steroid hormones and insulin on
the 7 day-old Ehrlich ascites tumor cells were studied in
vitro. The results of the present study showed that insulin
even at a high concentration of 20 jig/ml cannot stimulate the
increase in glucose carrier on Ehrlich ascites tumor cells.
However, both the glucagon and glucocorticoid can decrease the
density of glucose carrier in the tumor cells statistically
significantly by about 35%. The finding that Ehrlich ascites
tumor cells show response to glucagon and glucocorticoid but
not to insulin is difficult to explain. The transformation
from normal cells to malignant cells usually leads to a de-
differentiation and loss of a variety of cell apparatus includ-
ing some hormone receptors resulting insensitivity to such
hormones (Warburg 1956) and the result of present study may
suggest the loss of insulin receptor in Ehrlich ascites tumor
cells. Nirenberg (1959) show that Ehrlich ascites tumor cells
lack to a large extent of hormonal regulatory mechanism may be
through the loss or inhibition of particular enzyme pathways.
However, Ginsberg et al (1982) reported that insulin receptors
are present on Ehrlich ascites tumor cells and these receptors
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are biologically active. Pavelis et aZ (1979) showed that
the levels of insulin-like (glucose-lowing) substances in the
cell free extract from the Ehrhich ascites tumor cells are
higher than those in muscle extract indicating that insulin may
be required for tumor growth. On the other hand, Crane et aZ
(1956) also showed that insulin cannot show any stimulatory
effect on glucose uptake by Ehrlich ascites tumor cells and
our results are consistent with their finding. These may be a
compromised explanation that insulin effect on Ehrlich ascites
tumor cells may not be responsible for glucose uptake but for
other activity such as amino acids uptake or their incorporation
into proteins. The exact effect of insulin on Ehrlich ascites
tumor cells awaits further study. The decrease in glucose
carrier content in Ehrlich ascites tumor cells caused by glu-
cagon and corticosterone is surprising. Since the uptake of
glucose is essential for the proliferation of tumor cells, the
decrease in glucose carrier can lead to a decrease in glucose
uptake and thus to a decrease in tumor proliferation. However,
the characteristics of binding sites (receptors) for these
hormones on Ehrlich ascites tumor cells is still not clear.
Further studies in order to answer these questinos are needed.
In order to further confirm the effect of extracellular
glucose concentration on glucose carrier density in Ehrlich
ascites tumor cells, effect of different glucose concentrations
on 7 day-old Ehrlich ascites tumor cells were studied in vitro.
As the glucose in medium was metabolized by the tumor cells,
glucose concentration decreased progressively during the
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incubation. High glucose concentration in medium can decrease
the glucose carrier content in Ehrlich ascites tumor cells.
The repression of glucose carriers by high content of glucose
are reported in other cell lines (Maryineau et aZ 1972 Kalckar
and Ullrey 1973 Hatanaka 1973 Shaw and Amos 1973 Kletsien
and Perdue 1975 Salter and Cook 1975 Venuta and Rubin 1975
Salter ans Cook 1976 Christopher, Colby and Ullrey 1976
Musliner, Chrousos and Amos 1977). In high glucose group,
when the glucose concentration reached a critical lower level,
the Ehrlich ascites tumor cells were found to restore their
glucose carrier density (Fig. 27). On the other hand, in the
low glucose group, when the glucose in the medium was used up
at 8 hours after incubation, the tumor cells began to increase
their glucose carrier at 12 hours after glucose starvation.
The derepression of glucose carriers are also reported in
other cell lines (Amos et al 1977 Musliner, Chrousos and Amos
1977 Christopher, Colby and Ulirey 1976 Salter and Cook 1976)
The time lag for Ehrlich ascites tumor cells to increase
the glucose carrier after the prolonged glucose starvation may
suggest the involvement of protein synthesis in this respect.
It should be noted that at 2 hours after incubation, a small
drop in glucose carrier was observed in both high glucose and
low glucose groups, and this drop in glucose carrier may repre-
sent the adaption of tumor cells to the medium from peritoneal
cavities of mice because the reduction in glucose carrier is
nearly identical in both two groups.
The above results strongly suggest that repression and
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derepression of glucose carrier in response to glucose may
appear during Ehrlich ascites tumor cells development in vivo.
Therefore we postulate that when inoculated Ehrlich ascites
tumor cells were first exposed to the peritoneal fluid of
normal mice, where the glucose content was about 95 mg/100 ml,
so their. glucose carrier number decrease by the regulation of
repression. However during tumor development, the glucose level
in ascites fluid is undetectably low. Tumor cells may have to
increase their glucose carrier for facitilated uptake of
glucose. As serum glucose decrease progressively, the tumor
cells have to increase more their glucose carrier number.
This may be considered as a compensatory mechanism for glucose
uptake. This hypothesis is proven by the repression and de-
repression of glucose carrier according to the changes in glucose
concentration in vitro. However other factors being respon-
sible for the changes in glucose carriers on tumor cells may not
be ruled out. Lawrence and Jullien (1980) reported that Rous
sarcoma virus-transformed cells can release a factor that can
increase hexose transport by the transformed cells, and Todaro
and Larco (1978) showed that sarcoma-virus transformed cells
can produce a growth factor. Since increase in net body weight
of Ehrlich ascites tumor bearing mice was observed at early
state (Fig.2), and this increase in body weight may be due to
the factors with growth stimulating effect and these factors
may also influence the number of glucose carrier in the tumor
cells. However whether Ehrlich ascites tumor cells can produce
and release a factor (or factors) that can stimulate its proli-
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feration and glucose uptake is not known. Furthermore, Bernard
et aZ (1982) reported that during embryo development, the number
of glucose carrier increased in chick fibroblasts. The increase
in glucose carrier on Ehrlich ascites tumor cells may be just
a result of tumor development which is independent of other
factors.
VI. Effect of methorexate (MTX) on the glucose uptake and glucose
carrier on Ehrlich ascites tumor cells in vivo
It has been reported that methotrexate arrasts the growth
of Ehrlich ascites tumor cells by inhibiting nucleotide synthesis
and induction of a purineless state in cells (Hryniuk 1973).
The cytotoxic efficiency is dependent on the schedule of admin-
istration. Early administration was found to be more effective
(Table 7), an observation consistent with the cell cycle-specific
nature of methotrexate action (Ernst 1971) and the known relative
preponderance of resting cells in aged tumor (Lala and Patt
1966). M`FX also reduced the glucose uptake rate and the number
of glucose carrier in Ehrlich ascites tumor cells (Table 8
and Table 9), The efficiency of the drug in this respect roughly
paralleled its efficiency in reducing tumor size. In this
connection, it should be noted that glucose carrier on Ehrlich
ascites tumor cell is a protein (Cuppoletti, Mayhew and Jung
1981). MTX-induced depletion of nucleotide and the consequent
inhibition of DNA, RNA and protein synthesis might have con-
stituted primary chain of events leading to reduced glucose
carrier production. The reduction of the glucose uptake rate
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may be due directly to the reduction in glucose carrier.
vii. Scope for further s tudy
The present study provides more understanding to the char-
acteristics of glucose carrier on Ehrlich ascites tumor cells.
Since this carrier molecule has just been partially purified
(Cuppoletti, Mayhew and Jung 1981), its molecular structure is
still not clear. Nature of the binding of cytochalasin. B and
other sugars to this carrier molecule also remains unknown.
Deves and Krupka (1978) suggested that cytochalasin B asymmetri-
cally bound to human erythrocytes and Ginsburg (1978) suggested
that two simple asymmetric antiparallel carriers-with different
KM were responsible for hexose transport. In mammalian cell lines
including human Hela cells, mouse L- and P-388 leukemia cells,
Chinese hamster ovary cells and Novikoff rat hepatoma cells,
hexose transport system was found with broad substrate specifi-
city and differential molibilty of loaded and empty carrier,
but with directional symmetry (Graff, Wohlhueter and Plagemann
1981 Plagemann et al 1981). Studies on glucose carrier on
Ehrlich ascites tumor cells in this approach is also of interest.
Translocation of glucose carrier from microsomal pool to
plasma membrane was seen in adipocytes upon insulin stimulation.
Insulin was found without effect in the stimulation of glucose
carrier, however, whether translocation of glucose carrier
occurs in Ehrlich ascites tumor cells is not known and the
factor(s) and mechanism which stimulate translocation of glucose
carrier, if occurs, is also not understood.
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Although glucose starvation is strongly suggested to be
responsible for the changes in glucose carreir on Ehrlich
ascites tumor cells, the mechanism at molecular level of
glucose carrier repression and derepression caused by glucose
level is still obscure. To answer the above questions, further
studies on the nature of carrier on Ehrlich ascites tumor cells
are required.
Recently, several workers showed that anti-human erythro-
cyte glucose transporter antibody (Baldwin and Lienhard 1980)
can cross-react with the glucose transporer of rat adipocyte,
Rous sarcoma virus-transformed chick embryo fibroblasts, human
Hela cells and mouse L-1210 cell (Wheeler et a11982 Salter
et aZ 1982 Sogin and Hinkle 1980) and thus provide a new
dimension for the study in glucose transporter. Lienhard et
aZ (1982) made use of this technique to identify the glucose
transport with reponsiveness to insulin of rat adipocyte.
Since there are similarities in the nature of glucose trans-
porter shared by Ehrlich ascites tumor cells and other cell
lines, the antibody against human erythrocyte glucose trans-
porter may also cross-react with the glucose carrier on Ehrlich
ascites tumor cells and thus provide a new technique for the
study on the characteristics of glucose carrier of the tumor
cells.
Most recently, glucose carriers on human erythrocytes can
be photoaffinity labeled with 3H-cytochalasin B (Carter-Su et al
1982 Shanaha 1982). This new tecnique may be applicable in
the further studies on the nature and characteristics of glucose
carriers on Ehrlich ascites tumor cells.
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